NZ724797B2 - Yeast-brachyury immunotherapeutic compositions - Google Patents
Yeast-brachyury immunotherapeutic compositions Download PDFInfo
- Publication number
- NZ724797B2 NZ724797B2 NZ724797A NZ72479712A NZ724797B2 NZ 724797 B2 NZ724797 B2 NZ 724797B2 NZ 724797 A NZ724797 A NZ 724797A NZ 72479712 A NZ72479712 A NZ 72479712A NZ 724797 B2 NZ724797 B2 NZ 724797B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- yeast
- brachyury
- seq
- cancer
- antigen
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 245
- 230000001024 immunotherapeutic Effects 0.000 title claims abstract description 131
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 439
- 239000000427 antigen Substances 0.000 claims abstract description 349
- 102000038129 antigens Human genes 0.000 claims abstract description 347
- 108091007172 antigens Proteins 0.000 claims abstract description 347
- 201000011510 cancer Diseases 0.000 claims abstract description 254
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 82
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 71
- 102000037240 fusion proteins Human genes 0.000 claims abstract description 71
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 68
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 52
- 210000001744 T-Lymphocytes Anatomy 0.000 claims abstract description 45
- 108090001123 antibodies Proteins 0.000 claims abstract description 27
- 102000004965 antibodies Human genes 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 21
- 229960005486 vaccines Drugs 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 9
- 102100013137 CD40 Human genes 0.000 claims abstract 2
- 101710040446 CD40 Proteins 0.000 claims abstract 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 433
- 230000014509 gene expression Effects 0.000 claims description 119
- 150000001413 amino acids Chemical group 0.000 claims description 114
- 238000002560 therapeutic procedure Methods 0.000 claims description 52
- 150000002500 ions Chemical class 0.000 claims description 25
- 230000004927 fusion Effects 0.000 claims description 16
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 claims description 13
- 238000006467 substitution reaction Methods 0.000 claims description 13
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 12
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 claims description 12
- 230000000051 modifying Effects 0.000 claims description 12
- 239000004474 valine Substances 0.000 claims description 12
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 11
- 241000235070 Saccharomyces Species 0.000 claims description 9
- 210000003719 B-Lymphocytes Anatomy 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 241000235648 Pichia Species 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 7
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 229940035295 Ting Drugs 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 5
- 241000235346 Schizosaccharomyces Species 0.000 claims description 5
- 230000003442 weekly Effects 0.000 claims description 5
- 101710034857 ATIC Proteins 0.000 claims description 4
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 241000223252 Rhodotorula Species 0.000 claims description 4
- 241000235649 Kluyveromyces Species 0.000 claims description 3
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010017758 Gastric cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025310 Other lymphomas Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 206010046766 Uterine cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- 241000235013 Yarrowia Species 0.000 claims 2
- 208000009899 Burkitt Lymphoma Diseases 0.000 claims 1
- 101700013560 CUP1 Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 5
- 239000002955 immunomodulating agent Substances 0.000 abstract description 2
- 230000002584 immunomodulator Effects 0.000 abstract description 2
- 229940121354 immunomodulators Drugs 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 description 178
- 108090000623 proteins and genes Proteins 0.000 description 178
- 210000004027 cells Anatomy 0.000 description 169
- 239000003981 vehicle Substances 0.000 description 93
- 125000003275 alpha amino acid group Chemical group 0.000 description 73
- 238000009169 immunotherapy Methods 0.000 description 70
- 239000000556 agonist Substances 0.000 description 53
- 206010028980 Neoplasm Diseases 0.000 description 51
- 230000004044 response Effects 0.000 description 47
- 241000282414 Homo sapiens Species 0.000 description 45
- 210000004443 Dendritic Cells Anatomy 0.000 description 40
- 230000002163 immunogen Effects 0.000 description 39
- 230000028993 immune response Effects 0.000 description 37
- 239000002609 media Substances 0.000 description 37
- 210000004881 tumor cells Anatomy 0.000 description 34
- 230000001225 therapeutic Effects 0.000 description 30
- 108010008778 Brachyury protein Proteins 0.000 description 29
- 102100018674 TBXT Human genes 0.000 description 29
- 206010061289 Metastatic neoplasm Diseases 0.000 description 28
- 230000001939 inductive effect Effects 0.000 description 28
- 230000001394 metastastic Effects 0.000 description 28
- 238000000034 method Methods 0.000 description 28
- 230000002401 inhibitory effect Effects 0.000 description 27
- 210000002421 Cell Wall Anatomy 0.000 description 25
- 238000002512 chemotherapy Methods 0.000 description 25
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-Methionine Natural products CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 23
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 23
- 230000000638 stimulation Effects 0.000 description 23
- 229920001850 Nucleic acid sequence Polymers 0.000 description 22
- 230000027455 binding Effects 0.000 description 22
- 238000011161 development Methods 0.000 description 22
- 230000018109 developmental process Effects 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 21
- 102100011842 CEACAM5 Human genes 0.000 description 20
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 20
- 239000012528 membrane Substances 0.000 description 20
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 description 19
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 19
- 230000002708 enhancing Effects 0.000 description 18
- 230000003042 antagnostic Effects 0.000 description 17
- 239000005557 antagonist Substances 0.000 description 17
- 239000002245 particle Substances 0.000 description 17
- -1 MDRl Proteins 0.000 description 16
- 200000000023 metastatic cancer Diseases 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 238000002869 basic local alignment search tool Methods 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 238000001959 radiotherapy Methods 0.000 description 14
- ARUVKPQLZAKDPS-UHFFFAOYSA-L Copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 13
- 102000026088 HLA-A2 Antigen Human genes 0.000 description 13
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 13
- 230000004083 survival Effects 0.000 description 13
- 210000001519 tissues Anatomy 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 230000001603 reducing Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 11
- 108020004532 RAS Proteins 0.000 description 11
- 238000007792 addition Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 108020001180 rasD Proteins 0.000 description 11
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 description 10
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 9
- 230000001809 detectable Effects 0.000 description 9
- 102000027675 major histocompatibility complex family Human genes 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000006011 modification reaction Methods 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- 102100007495 AR Human genes 0.000 description 8
- 102100006400 CSF2 Human genes 0.000 description 8
- 101710038745 EEF1A2 Proteins 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 102100005038 SPOP Human genes 0.000 description 8
- 101700060127 SPOP Proteins 0.000 description 8
- 101710005270 TEF1 Proteins 0.000 description 8
- 108010080146 androgen receptors Proteins 0.000 description 8
- 238000004166 bioassay Methods 0.000 description 8
- 230000003247 decreasing Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000003899 glycosylation Effects 0.000 description 8
- 238000006206 glycosylation reaction Methods 0.000 description 8
- 230000001965 increased Effects 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 230000001264 neutralization Effects 0.000 description 8
- 206010056981 Adenomatous polyposis coli Diseases 0.000 description 7
- 239000004475 Arginine Substances 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 101710008404 GAPDH Proteins 0.000 description 7
- 102000008100 Human Serum Albumin Human genes 0.000 description 7
- 108091006822 Human Serum Albumin Proteins 0.000 description 7
- DRTQHJPVMGBUCF-UCVXFZOQSA-N Uridine Natural products O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 description 7
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 7
- 229940045145 Uridine Drugs 0.000 description 7
- 102000006108 VHL Human genes 0.000 description 7
- 108060009310 VHL Proteins 0.000 description 7
- 101710025952 adhT Proteins 0.000 description 7
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000021633 leukocyte mediated immunity Effects 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 229920000023 polynucleotide Polymers 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000002271 resection Methods 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 210000000987 Immune System Anatomy 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 6
- 229910000365 copper sulfate Inorganic materials 0.000 description 6
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000004481 post-translational protein modification Effects 0.000 description 6
- 230000001105 regulatory Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 230000001131 transforming Effects 0.000 description 6
- 210000000349 Chromosomes Anatomy 0.000 description 5
- 101710037135 GAPC2 Proteins 0.000 description 5
- 101710037116 GAPC3 Proteins 0.000 description 5
- 101710025049 GAPDG Proteins 0.000 description 5
- 102100006425 GAPDH Human genes 0.000 description 5
- 101710010461 Gapdh1 Proteins 0.000 description 5
- 102100014204 IL22 Human genes 0.000 description 5
- 108010065805 Interleukin-12 Proteins 0.000 description 5
- 102000013462 Interleukin-12 Human genes 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- 101710025050 MK0970 Proteins 0.000 description 5
- 108020004999 Messenger RNA Proteins 0.000 description 5
- 206010027476 Metastasis Diseases 0.000 description 5
- 206010064390 Tumour invasion Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 101710025091 cbbGC Proteins 0.000 description 5
- 108010035432 cytochrome C(L) Proteins 0.000 description 5
- 230000004059 degradation Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 101710025070 gapdh-2 Proteins 0.000 description 5
- 230000028996 humoral immune response Effects 0.000 description 5
- 230000002519 immonomodulatory Effects 0.000 description 5
- 230000003902 lesions Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 229920002106 messenger RNA Polymers 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 4
- 102100017392 ANO7 Human genes 0.000 description 4
- 101700064647 ANO7 Proteins 0.000 description 4
- 229960000643 Adenine Drugs 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
- 210000000481 Breast Anatomy 0.000 description 4
- 101710004105 DCT Proteins 0.000 description 4
- 102100007097 DCT Human genes 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 4
- 102000003425 EC 1.14.18.1 Human genes 0.000 description 4
- 108060008724 EC 1.14.18.1 Proteins 0.000 description 4
- 108060002563 EPCAM Proteins 0.000 description 4
- 101700025368 ERBB2 Proteins 0.000 description 4
- 102100016662 ERBB2 Human genes 0.000 description 4
- 101710009074 FLT3 Proteins 0.000 description 4
- 102100008453 FOLH1 Human genes 0.000 description 4
- 101700036477 FOLH1 Proteins 0.000 description 4
- 241000578472 Human endogenous retrovirus H Species 0.000 description 4
- 241000192019 Human endogenous retrovirus K Species 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 101700058542 KLK3 Proteins 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- 210000004072 Lung Anatomy 0.000 description 4
- 102100006044 MUC16 Human genes 0.000 description 4
- 101700008449 MUC16 Proteins 0.000 description 4
- 102100013951 MUC2 Human genes 0.000 description 4
- 101700036633 MUC2 Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 101710027788 NPEPPS Proteins 0.000 description 4
- 101710025567 PSAT1 Proteins 0.000 description 4
- 101700008337 PSMA Proteins 0.000 description 4
- 102000004503 Perforin Human genes 0.000 description 4
- 108010056995 Perforin Proteins 0.000 description 4
- 101700044827 RNMT Proteins 0.000 description 4
- 102100017680 SMAD4 Human genes 0.000 description 4
- 108010050282 Smad4 Protein Proteins 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 101710009757 UROD Proteins 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 125000004429 atoms Chemical group 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 description 4
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 description 4
- 102000015694 estrogen receptors Human genes 0.000 description 4
- 108010038795 estrogen receptors Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 239000000367 immunologic factor Substances 0.000 description 4
- 230000003308 immunostimulating Effects 0.000 description 4
- 230000000415 inactivating Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000003278 mimic Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000001717 pathogenic Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000000546 pharmaceutic aid Substances 0.000 description 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 4
- 230000000770 pro-inflamatory Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 230000003612 virological Effects 0.000 description 4
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102100010912 EPCAM Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229960000310 ISOLEUCINE Drugs 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- 108060004270 LAG3 Proteins 0.000 description 3
- 102100017213 LAG3 Human genes 0.000 description 3
- 102100002997 NPEPPS Human genes 0.000 description 3
- 102000011755 Phosphoglycerate kinases Human genes 0.000 description 3
- 108020004454 Phosphoglycerate kinases Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 102100009594 TPI1 Human genes 0.000 description 3
- 208000001756 Virus Disease Diseases 0.000 description 3
- 230000000240 adjuvant Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000735 allogeneic Effects 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 201000009910 diseases by infectious agent Diseases 0.000 description 3
- 210000003162 effector T lymphocyte Anatomy 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000001976 improved Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000002147 killing Effects 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 230000002934 lysing Effects 0.000 description 3
- 230000003211 malignant Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 102000003735 mesothelin Human genes 0.000 description 3
- 108090000015 mesothelin Proteins 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 108010045030 monoclonal antibodies Proteins 0.000 description 3
- 102000005614 monoclonal antibodies Human genes 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 108020000411 toll-like receptors Proteins 0.000 description 3
- 102000002689 toll-like receptors Human genes 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 102000003995 transcription factors Human genes 0.000 description 3
- 108090000464 transcription factors Proteins 0.000 description 3
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 2
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100003729 CD40LG Human genes 0.000 description 2
- 101710004053 CWINV2 Proteins 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 210000003855 Cell Nucleus Anatomy 0.000 description 2
- 210000001072 Colon Anatomy 0.000 description 2
- 210000000805 Cytoplasm Anatomy 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108020004445 Glyceraldehyde-3-Phosphate Dehydrogenases Proteins 0.000 description 2
- 102000006602 Glyceraldehyde-3-Phosphate Dehydrogenases Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 102000003964 Histone deacetylases Human genes 0.000 description 2
- 108090000353 Histone deacetylases Proteins 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- 229960000367 Inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N Inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- 244000285963 Kluyveromyces fragilis Species 0.000 description 2
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 2
- 241001138401 Kluyveromyces lactis Species 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- 210000001165 Lymph Nodes Anatomy 0.000 description 2
- 210000003470 Mitochondria Anatomy 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 210000004940 Nucleus Anatomy 0.000 description 2
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 2
- 210000001672 Ovary Anatomy 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- 108091005771 Peptidases Proteins 0.000 description 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N Pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 210000002307 Prostate Anatomy 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101700062671 SIAE Proteins 0.000 description 2
- 101700016532 SUC2 Proteins 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- 210000000952 Spleen Anatomy 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- 108060003967 TIM Proteins 0.000 description 2
- 102100012087 TLR4 Human genes 0.000 description 2
- 101700022711 TLR4 Proteins 0.000 description 2
- 210000001550 Testis Anatomy 0.000 description 2
- 229960003433 Thalidomide Drugs 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- 229940035893 Uracil Drugs 0.000 description 2
- 210000003932 Urinary Bladder Anatomy 0.000 description 2
- 206010047461 Viral infection Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 230000002730 additional Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001028 anti-proliferant Effects 0.000 description 2
- 230000000890 antigenic Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 201000009030 carcinoma Diseases 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000000139 costimulatory Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002458 infectious Effects 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 238000002665 ion therapy Methods 0.000 description 2
- 229960004942 lenalidomide Drugs 0.000 description 2
- 230000004301 light adaptation Effects 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 238000011068 load Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 210000003071 memory T lymphocyte Anatomy 0.000 description 2
- 230000000813 microbial Effects 0.000 description 2
- 230000001617 migratory Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 108091008124 oncoproteins Proteins 0.000 description 2
- 102000025475 oncoproteins Human genes 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229960000688 pomalidomide Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 230000001737 promoting Effects 0.000 description 2
- 230000002633 protecting Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 210000001938 protoplasts Anatomy 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101710025069 yplQ Proteins 0.000 description 2
- 101700002069 ARPD Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 108010090838 Alemtuzumab Proteins 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- 229920002395 Aptamer Polymers 0.000 description 1
- 229940046844 Aromatase inhibitors Drugs 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N Bis-tris methane Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 235000003197 Byrsonima crassifolia Nutrition 0.000 description 1
- 240000001546 Byrsonima crassifolia Species 0.000 description 1
- 101700003485 CSF2 Proteins 0.000 description 1
- 229940112129 Campath Drugs 0.000 description 1
- 229940095731 Candida albicans Drugs 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 210000001715 Carotid Arteries Anatomy 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 229920001405 Coding region Polymers 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- 229920000453 Consensus sequence Polymers 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 210000000172 Cytosol Anatomy 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010082433 EC 2.7.7.12 Proteins 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 229940047652 Ear Drops Drugs 0.000 description 1
- 210000002472 Endoplasmic Reticulum Anatomy 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940012356 Eye Drops Drugs 0.000 description 1
- 102100004572 FLT3LG Human genes 0.000 description 1
- 101710022257 FLT3LG Proteins 0.000 description 1
- 101700064140 FOXP3 Proteins 0.000 description 1
- 102100011855 FOXP3 Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108090000698 Formate Dehydrogenases Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101700058973 GAL4 Proteins 0.000 description 1
- 102100008842 GH1 Human genes 0.000 description 1
- 102000016876 Galactokinase Human genes 0.000 description 1
- 108091000074 Galactokinase Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101710006488 HSPA4 Proteins 0.000 description 1
- 244000286779 Hansenula anomala Species 0.000 description 1
- 235000014683 Hansenula anomala Nutrition 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000125500 Hedypnois rhagadioloides Species 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
- 101710006493 Hsp70Bb Proteins 0.000 description 1
- 102100014201 IL23R Human genes 0.000 description 1
- 102100008627 IL27RA Human genes 0.000 description 1
- 101700082799 IL2RA Proteins 0.000 description 1
- 101700015336 ISG20 Proteins 0.000 description 1
- 102100002950 ISG20 Human genes 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 229940117681 Interleukin-12 Drugs 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102100011539 LGALS4 Human genes 0.000 description 1
- 101710015850 LGALS4 Proteins 0.000 description 1
- 229940087875 Leukine Drugs 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010025135 Lupus erythematosus Diseases 0.000 description 1
- 210000002751 Lymph Anatomy 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N M-Cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 102100000541 MARK2 Human genes 0.000 description 1
- 101700064507 MARK2 Proteins 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102400000108 N-terminal peptide Human genes 0.000 description 1
- 101800000597 N-terminal peptide Proteins 0.000 description 1
- 229940100662 Nasal Drops Drugs 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 241001182492 Nes Species 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- QWVGKYWNOKOFNN-UHFFFAOYSA-N O-Cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 1
- 229940116542 OTHER NUTRIENTS in ATC Drugs 0.000 description 1
- 229940100027 Ontak Drugs 0.000 description 1
- 210000003463 Organelles Anatomy 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 108020005203 Oxidases Proteins 0.000 description 1
- 102100010734 PRL Human genes 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 241000222051 Papiliotrema laurentii Species 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N Phosphoenolpyruvic acid Natural products OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 231100000614 Poison Toxicity 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 210000000173 Precursor Cells, T-Lymphoid Anatomy 0.000 description 1
- 229940097325 Prolactin Drugs 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010056342 Pulmonary mass Diseases 0.000 description 1
- 101710037934 QRSL1 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010033725 Recombinant Proteins Proteins 0.000 description 1
- 102000007312 Recombinant Proteins Human genes 0.000 description 1
- 210000003660 Reticulum Anatomy 0.000 description 1
- 229940120975 Revlimid Drugs 0.000 description 1
- 241000223254 Rhodotorula mucilaginosa Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000007697 Saccharomyces cerevisiae W303 Species 0.000 description 1
- 235000011859 Saccharomyces cerevisiae W303 Nutrition 0.000 description 1
- 241001123227 Saccharomyces pastorianus Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 241000267154 Southern tomato virus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 1
- 108091008153 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 102000005924 Triose-phosphate isomerases Human genes 0.000 description 1
- 108020003073 Triose-phosphate isomerases Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010075202 UDPglucose 4-Epimerase Proteins 0.000 description 1
- 210000004291 Uterus Anatomy 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 210000002268 Wool Anatomy 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent Effects 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitors Drugs 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001746 atrial Effects 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceuticals Drugs 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000007336 cryptococcosis Diseases 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000001461 cytolytic Effects 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003467 diminishing Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 230000000534 elicitor Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000003344 immunostimulant Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 description 1
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 description 1
- 108010027445 interleukin-22 receptor Proteins 0.000 description 1
- 102000009548 interleukin-22 receptor activity proteins Human genes 0.000 description 1
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 description 1
- 108040010248 interleukin-25 receptor activity proteins Proteins 0.000 description 1
- 108040010246 interleukin-27 receptor activity proteins Proteins 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000000527 lymphocytic Effects 0.000 description 1
- 230000002101 lytic Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 101700061289 mnn9 Proteins 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000771 oncological Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 238000005222 photoaffinity labeling Methods 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000003362 replicative Effects 0.000 description 1
- 108091007521 restriction endonucleases Proteins 0.000 description 1
- 102000027730 retinoid hormone receptors Human genes 0.000 description 1
- 108091008001 retinoid hormone receptors Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000001340 slower Effects 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- NESXXUAWVHXRGX-UHFFFAOYSA-M sodium;1-carboxyethenyl hydrogen phosphate Chemical compound [Na+].OP(O)(=O)OC(=C)C([O-])=O NESXXUAWVHXRGX-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000730 tolerability Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
Abstract
Discloses the use of an immunotherapeutic composition comrpising a yeast vehicle, a Brachyury antigen and a further agent selected from the group consisting of an immunotherapeutic virus-based vaccine, a cytokine, a T-cell co-stimulator, a immunomodulator, CD40, anti-CTLA-4 antibody, anti-PD-1, anti-PD-L1, anti-PD-L2 in the manufacture of a medicament for treating cancer. Further discloses a recombinant nucleic acid molecule encoding a fusion protein comprising at least one Brachyury antigen. -PD-L1, anti-PD-L2 in the manufacture of a medicament for treating cancer. Further discloses a recombinant nucleic acid molecule encoding a fusion protein comprising at least one Brachyury antigen.
Description
Yeast-Brachyury Immunotherapeutic Compositions
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of priority under 35 U.S.C. §119(e) to U.S.
Provisional Application Serial No. 61/453,656, filed March 17, 2011. The entire disclosure of
U.S. Provisional Application Serial No. 61/453,656, filed March 17, 2011 is incorporated
herein by reference.
[0001A] This application is a divisional of New Zealand Patent Application No. 711188, in
turn, a divisional application of New Zealand Patent ation No. , the entire
contents of which are herein incorporated by reference.
GOVERNMENT RIGHTS
This invention was d in the performance of a Cooperative Research and
Development Agreement with the National Institutes of Health, an Agency of the Department
of Health and Human Services. The ment of the United States has certain rights in this
invention.
STATEMENT ING JOINT CH AGREEMENT
This invention was made by or on behalf of parties to a Cooperative Research and
Development Agreement, executed May 8, 2008. The parties to the Cooperative Research and
Development Agreement are: GlobeImmune, Inc. and the U.S. Department of Health and
Human Services, as represented by National Cancer Institute, an Institute, Center or Division
of the al Institutes of Health.
REFERENCE TO A SEQUENCE LISTING
This application ns a Sequence Listing submitted electronically as a text file
by EFS-Web. The text file, named "3923PCT_ST25", has a size in bytes of 76 KB, and
was recorded on 13 March 2012. The information contained in the text file is incorporated
herein by reference in its entirety pursuant to 37 CFR § 1.52(e)(5).
FIELD OF THE INVENTION
The present invention generally relates to yeast-based therapeutic
compositions and methods for the prevention and/or treatment of cancers characterized by the
expression or pression of Brachyury.
BACKGROUND OF THE INVENTION
Brachyury, also known as “T”, is a mesodermal transcription factor and member
of the T-box x of genes. The gene encoding Brachyury (denoted as either T gene or
Brachyury gene in humans) was initially identified in 1927 by Nadine Dobrovolskaïa-
Zavadskaïa through a mutation in mice that ed tail length and sacral vertebrae in
heterozygous animals. The ury gene was cloned in mice in 1990 by Hermann and
colleagues (Herrmann et al., 1990, Nature 343:617-622) and in humans in
1996 by Edwards and colleagues (Edwards et al., 1996, Genome Res. 6:226-223), who
also described the deduced amino acid ce for human Brachyury.
As a member of the T-box family of transcription factors, Brachyury contains
the highly conserved DNA-binding domain motif, called “T-box” or T-domain, which
binds to a palindromic consensus sequence. ury, like other T-box proteins, has
been shown to play a role in early development, and is vital for the formation and
entiation of posterior rm and axial development in vertebrates (see, e.g.,
Wilkinson et al., 1990, Nature 343(6259):657—659); Beddington et al., 1992, Development
(Suppl.):157-165; e-Merker et al., 1994, Development 120: 1009-1015; Kispert and
Herrmann, 1994, Dev. Biol. 161:179-193; Showell et al., 2004, Dev Dyn 229:201-218).
More recently, Palena and colleagues have demonstrated that Brachyury is expressed in a
y of human tumor tissues and cancer cell lines and have shown that peptides of
Brachyury can be used to generate Brachyury-specific T cell lines in normal donors and
cancer patients (Palena et al., 2007, Clin. Cancer Res. 13(8):2471-2478). Studies by
Fernando et al. have shown that Brachyury promotes the epithelial-mesenchymal
transition (EMT) in human tumor cells, conferring on tumor cells a mesenchymal
phenotype, as well as migratory and ve abilities, while attenuating tumor cell cycle
progression (Fernando et al., 2010, J. Clin. Invest. 120(2):533-544). Accordingly,
Brachyury is involved in metastatic progression of cancer.
Cancer is a leading cause of death worldwide, and the development of
effective therapies for cancer continues to be one of the most active areas of research and
al development. Although a variety of innovative approaches to treat and prevent
cancers have been proposed, many cancers continue to have a high rate of mortality and
may be lt to treat or relatively onsive to conventional therapies. Cancers
associated with Brachyury expression may be found in a variety of tissues, including
breast, small intestine, stomach, kidney, bladder, uterus, ovary, testes, lung, colon and
prostate, and includes metastatic and late-stage s. In on, Brachyury is
expressed in tumors of B cell origin, such as chronic lymphocytic leukemia (CLL),
Epstein-Barr virus transformed B cells, Burkitt’s and n’s lymphomas. Therefore,
Brachyury appears to play a role in a large number of human cancers. While Brachyury
has been proposed to be a target for cancer immunotherapy (see, e. g., Palena et al., supra,
Fernando et al., supra, and WC 2008/106551), since this is a relatively new cancer target,
there remains a need in the art for new immunotherapeutic products that effectively treat
and/or prevent cancers associated with ury sion or overexpression.
SUMMARY OF THE INVENTION
One embodiment of the invention relates to a method to reduce, arrest, reverse,
delay or prevent the metastatic progression of cancer in an individual Who has cancer. The
method includes the step of administering to an dual Who has a cancer that is
undergoing metastatic progression, is at risk of undergoing metastatic ssion, or is
predicted to begin undergoing metastatic progression, an immunotherapeutic composition
comprising: (a) a yeast e; and (b) a cancer antigen comprising at least one Brachyury
antigen. Another ment of the invention relates to the use of an immunotherapeutic
composition comprising a yeast e and a cancer antigen comprising at least one
Brachyury antigen to reduce, arrest, reverse or prevent the metastatic progression of
cancer in an individual who has cancer.
In one aspect, of these embodiments of the invention, Brachyury is not
detected in the dual’s cancer at the time the composition is first administered. In one
aspect, Brachyury expression is detected in the individual’s cancer at the time the
composition is first administered. The individual may have stage I cancer, stage II cancer,
stage III , or stage IV cancer.
Another embodiment of the invention relates to a method to prevent or delay
the onset of a Brachyury-expressing cancer. The method includes the step of
administering to an individual an immunotherapeutic composition comprising: (a) a yeast
vehicle; and (b) a cancer antigen comprising at least one Brachyury antigen. Another
embodiment of the invention relates to the use of an immunotherapeutic composition
comprising a yeast vehicle and a cancer antigen comprising at least one ury n
to prevent or delay the onset of a Brachyury-expressing cancer.
In one aspect of these embodiments, cancer has not been ed in the
individual. In one aspect, the individual is at high risk for developing cancer (e.g., via a
c predisposition). In one aspect, the individual has a pre-cancerous .
In one aspect of these embodiments, the individual has cancer, but ury-
expressing cancer cells have not been detected in the cancer. In one aspect, the cancer is
not yet metastatic. In one aspect, the cancer has a high risk of metastasizing. In one
aspect, the subject has stage I cancer. In one aspect, the subject has stage II .
Another embodiment of the invention relates to a method to reduce or t
chemotherapy-resistance or radiation-resistance of tumor cells in a patient With cancer.
The method includes the steps of administering to an individual Who has cancer and is
receiving chemotherapy and/or radiation therapy an immunotherapeutic composition
comprising: (a) a yeast vehicle; and (b) a cancer antigen comprising at least one ury
n. Another embodiment of the invention relates to the use of an immunotherapeutic
composition comprising a yeast vehicle and a cancer n comprising at least one
Brachyury n to reduce or prevent chemotherapy-resistance or radiation-resistance of
tumor cells in a patient With cancer. In one aspect of this embodiment of the invention,
Brachyury is not detected in the individual’s cancer at the time the ition is first
stered. In one aspect, Brachyury expression is detected in the individual’s cancer at
the time the composition is first administered.
Yet another embodiment of the invention relates to a method to treat cancer.
The method includes the steps of: (a) administering to an individual Who has cancer in
Which Brachyury expression has not been detected, a first immunotherapeutic composition
comprising a yeast vehicle and a first cancer antigen that does not comprise a ury
n; and (b) administering to the individual, prior to, concurrently With, sequentially
With, or subsequent to, administration of the first immunotherapeutic composition a
second immunotherapeutic composition comprising a yeast vehicle and a second cancer
antigen comprising a Brachyury antigen. In one aspect, the method further comprises, in
step (a), administering one or more additional immunotherapeutic compositions, wherein
the each of the one or more additional immunotherapeutic compositions comprises an
additional cancer antigen. In one aspect of either embodiment above, the cancer antigen is
selected from: d Ras, carcinoembryonic antigen (CEA), MUC-l, EGFR, BCR-Abl,
MART-l, MAGE-l, MAGE-3, GAGE, GP-lOO, MUC-2, PSMA, tyrosinase, TRP-l
(gp75), NY-ESO-l, TRP-2, TAG72, KSA, CA-125, PSA, HER-2/neu/c-erb/B2, hTERT,
p73, B-RAF, adenomatous polyposis coli (APC), Myc, von Hippel-Lindau protein (VHL),
Rb-l, Rb-2, androgen receptor (AR), Smad4, MDRl, Flt-3, BRCA-l, BRCA-2, pax3-fl<hr,
ews-fii-l, HERV-H, HERV-K, TWIST, elin, and NGEP. In one , the cancer
antigen is selected from the group consisting of: mutated Ras, carcinoembryonic antigen
(CEA), and MUC-l. Another embodiment of the invention relates to the use of a
combination of immunotherapeutic compositions to treat cancer, the immunotherapeutic
compositions comprising: (a) a first therapeutic composition comprising a yeast
vehicle and a first cancer antigen that does not comprise a Brachyury antigen; and (b) a
second therapeutic composition comprising a yeast vehicle and a second cancer
antigen comprising a ury antigen.
Yet another embodiment of the invention relates to a method treat cancer. The
method includes the steps of: (a) administering to an individual Who has cancer a first
immunotherapeutic composition comprising a yeast vehicle and a mutated Ras antigen; (b)
administering to the individual of (a) a second immunotherapeutic composition
comprising a yeast vehicle and an antigen selected from the group consisting of
carcinoembryonic antigen (CEA) and mucin-l (MUC-l); and (c) administering to the
individual of (a) and (b) a third immunotherapeutic ition comprising a yeast
vehicle and a Brachyury antigen. In one aspect, the steps of stration in (a), (b) and
(c) are concurrent. Another embodiment of the invention relates to the use of a
combination of immunotherapeutic compositions to treat cancer, the immunotherapeutic
compositions comprising: (a) a first immunotherapeutic composition sing a yeast
vehicle and a mutated Ras antigen; (b) a second immunotherapeutic composition
comprising a yeast vehicle and an antigen ed from the group consisting of
oembryonic antigen (CEA) and mucin-l (MUC-l); and (c) a third
immunotherapeutic ition comprising a yeast vehicle and a Brachyury antigen.
In any of the embodiments or aspects of the invention described above or
ere herein, where the individual has cancer or a precancerous lesion, in one aspect
of the invention, the individual is being treated or has been treated with another therapy
for cancer. For example, such a therapy can include, but is not limited to, herapy,
targeted cancer therapy, radiation therapy, adoptive T cell transfer, and/or administration
of one or more additional therapeutic compositions. In one , an additional
immunotherapeutic composition comprises a yeast vehicle and a second cancer n
that does not include Brachyury antigen. The second cancer antigen can include, but is not
limited to, mutated Ras, carcinoembryonic antigen (CEA), MUC-l, EGFR, BCR-Abl,
MART-l, , MAGE-3, GAGE, GP-lOO, MUC-2, PSMA, tyrosinase, TRP-l
(gp75), NY-ESO-l, TRP-2, TAG72, KSA, CA-125, PSA, HER-2/neu/c-erb/B2, hTERT,
p73, B-RAF, adenomatous polyposis coli (APC), Myc, von Hippel-Lindau protein (VHL),
Rb-l, Rb-2, androgen receptor (AR), Smad4, MDRl, Flt-3, BRCA-l, BRCA-2, pax3-fl<hr,
ews-fli-l, HERV-H, HERV-K, TWIST, Mesothelin, and NGEP. In one aspect, the second
cancer antigen is ed from: mutated Ras, carcinoembryonic antigen (CEA), and
MUC-l.
In one aspect of any of the embodiments or aspects of the invention bed
above or elsewhere herein, the method or use reduces tumor burden in the individual,
increases survival of the individual, and/or ts tumor growth in the individual.
In one aspect of any of the embodiments or aspects of the invention described
above or elsewhere herein, the method further comprises surgical resection of a tumor
from the individual.
In one aspect of any of the ments or s of the invention bed
above or elsewhere herein, the cancer is of epithelial cell origin. In one aspect, the cancer
can include, but is not limited to, breast cancer, small intestine cancer, stomach cancer,
pancreatic cancer, kidney cancer, bladder cancer, uterine cancer, ovarian cancer, testicular
cancer, lung cancer, colon cancer, prostate cancer, chronic lymphocytic ia (CLL),
Epstein-Barr virus transformed B cells, t’s lymphoma, Hodgkin’s lymphoma, or
metastatic cancers thereof.
In one aspect of any of the embodiments or s of the invention described
above or elsewhere herein, the Brachyury antigen is full-length human Brachyury. In one
, the Brachyury antigen is not full-length Brachyury. In one , the Brachyury
antigen has an amino acid sequence represented by SEQ ID NO:6, SEQ ID NOil8, SEQ
ID N02, or an amino acid sequence that is at least 95% identical to SEQ ID NO:6, SEQ
ID NOil8, or SEQ ID NO:2. In one aspect, the Brachyury antigen comprises from at least
position 1 or 2 to n position 255 and the C-terminus of SEQ ID NO:6, SEQ ID
NOil8, or SEQ ID NO:2. In one aspect, the Brachyury antigen comprises from at least
position 1 or 2 to between position 430 and the C-terminus of SEQ ID NO:6, SEQ ID
NOil8, or SEQ ID NO:2. In one aspect, the Brachyury n comprises positions 246 to
254 of SEQ ID NO:6, SEQ ID NOil8, or SEQ ID NO:2. In one aspect, the Brachyury
antigen comprises SEQ ID NO:6, positions 2-435 of SEQ ID NO:6, or an amino acid
sequence that is at least 95% identical to SEQ ID NO:6. In one aspect, the Brachyury
antigen comprises SEQ ID NO:l8, ons 2-435 of SEQ ID NO:l8, or an amino acid
sequence that is at least 95% identical to SEQ ID NO:l8. In one aspect, the Brachyury
antigen comprises SEQ ID NO:2, positions 2-435 of SEQ ID N02, or an amino acid
sequence that is at least 95% identical to SEQ ID NO:2. In one aspect, the Brachyury
antigen comprises SEQ ID NO:6, positions 2-435 of SEQ ID NO:6, or an amino acid
sequence that is at least 99% identical to SEQ ID NO:6. In one aspect, the Brachyury
antigen comprises SEQ ID NO:l8, positions 2-435 of SEQ ID NO:l8, or an amino acid
sequence that is at least 99% identical to SEQ ID NO:l8. In one aspect, the Brachyury
antigen ses SEQ ID NO:2, positions 2-435 of SEQ ID N02, or an amino acid
sequence that is at least 99% identical to SEQ ID NO:2. In one aspect, the cancer antigen
is at least 25 amino acids in length. In one aspect, the ury antigen is at least 25
amino acids in length. In one , the Brachyury antigen is r than 30 amino acids
in length. In one aspect, the cancer antigen comprises two or more immunogenic s
of Brachyury.
In one aspect of any of the embodiments or aspects of the invention described
above or elsewhere herein, the cancer antigen is a fusion protein. In one , the fusion
protein has an amino acid sequence represented by SEQ ID NO:8, or an amino acid
sequence that is at least 95% identical to SEQ ID NO:8. In one aspect, the fusion protein
has an amino acid sequence represented by SEQ ID NO:20, or an amino acid sequence
that is at least 95% identical to SEQ ID NO:20.
r embodiment of the ion relates to a yeast-Brachyury
immunotherapeutic composition, wherein the immunotherapeutic composition comprises:
(a) a yeast vehicle; and (b) an antigen expressed by the yeast vehicle and comprising at
least one Brachyury antigen, wherein the Brachyury antigen comprises greater than 30
amino acids of an amino acid sequence represented by SEQ ID NO:6, SEQ ID NO:l8 or
SEQ ID NO:2. In one aspect, the Brachyury antigen comprises an amino acid sequence
that is at least 95% identical to SEQ ID NO:6, SEQ ID NO:l8 or SEQ ID NO:2. In one
aspect, the Brachyury antigen comprises from at least position 1 or 2 to between position
255 and the C-terminus of SEQ ID NO:6, SEQ ID NO:l8 or SEQ ID NO:2. In one aspect,
the Brachyury antigen comprises from at least position 1 or 2 to between position 430 and
the C-terminus of SEQ ID NO:6, SEQ ID NO:l8 or SEQ ID NO:2. In one aspect, the
Brachyury antigen comprises positions 246 to 254 of SEQ ID NO:6, SEQ ID NOil8 or
SEQ ID NO:2. In one , the Brachyury antigen comprises SEQ ID NO:6, positions
2-435 of SEQ ID NO:6, or an amino acid sequence that is at least 95% identical to SEQ ID
NO:6. In one aspect, the Brachyury antigen comprises SEQ ID NO:18, positions 2-435 of
SEQ ID NO:l8, or an amino acid sequence that is at least 95% identical to SEQ ID NOil8.
In one , the Brachyury antigen comprises SEQ ID NO:2, positions 2-435 of SEQ ID
N02, or an amino acid sequence that is at least 95% cal to SEQ ID NO:2. In one
aspect, the Brachyury antigen comprises SEQ ID NO:6, ons 2-435 of SEQ ID NO:6,
or an amino acid ce that is at least 99% identical to SEQ ID NO:6. In one aspect,
the Brachyury antigen comprises SEQ ID NO:l8, positions 2-435 of SEQ ID NOil8, or an
amino acid sequence that is at least 99% identical to SEQ ID NO:18. In one aspect, the
Brachyury antigen comprises SEQ ID NO:2, positions 2-435 of SEQ ID N02, or an
amino acid ce that is at least 99% identical to SEQ ID NO:2. In one aspect, the
cancer antigen is a fusion n. In one aspect, the fusion protein has an amino acid
sequence that is SEQ ID NO:8 or an amino acid sequence that is at least 95% identical to
SEQ ID NO:8. In one aspect, the fusion n has an amino acid sequence of SEQ ID
NO:20 or an amino acid sequence that is at least 95% cal to SEQ ID NO:20. In one
aspect, the yeast vehicle is a whole yeast. In one aspect, the whole yeast is heat-
inactivated.
Yet another embodiment of the invention relates to a yeast-Brachyury
immunotherapeutic composition comprising: (a) a whole, vated yeast; and (b) a
ury fusion protein comprising the amino acid sequence of positions 2-435 of SEQ
ID NO:6. The expression of the Brachyury fusion protein is under the control of the
promoter CUPI , the Brachyury fusion protein is expressed by the yeast, and the
composition elicits a Brachyury-specific T cell response. In one aspect, the fusion protein
comprises the amino acid sequence of SEQ ID NO:8.
Yet another embodiment of the invention relates to a yeast-Brachyury
immunotherapeutic composition comprising: (a) a whole, inactivated yeast; and (b) a
ury fusion protein comprising the amino acid sequence of positions 2-435 of SEQ
ID NOil8. The expression of the Brachyury fusion protein is under the control of the
promoter CUPI , the Brachyury fusion n is expressed by the yeast, and the
composition elicits a Brachyury-specific T cell response. In one aspect, the fusion protein
comprises the amino acid sequence of SEQ ID NO:20.
In one aspect of any of the embodiments or aspects of the invention described
above or elsewhere herein, the yeast vehicle is a whole yeast. In one aspect, the whole
yeast is killed. In one aspect, the whole yeast is heat-inactivated. In one aspect, the yeast
expresses the antigen. In one aspect, the yeast is from a genus ed from the group
consisting of: Saccharomyces, Candida, Cryptococcus, Hansenula, Kluyveromyces,
, Rhodotorula, Schizosaccharomyces and Yarrowz'a. In one aspect, the yeast is from
Saccharomyces. In one aspect, the yeast is from Saccharomyces siae.
In one aspect of any of the embodiments of the invention described above or
elsewhere herein, the composition is formulated in a pharmaceutically acceptable
excipient suitable for administration to a t.
Yet r embodiment of the invention relates to the use of any of the yeast-
Brachyury immunotherapeutic compositions described herein to treat a disease. In one
aspect, the disease is cancer. In one aspect, the disease is ated with an infectious
agent. In one aspect, the disease is associated with a virus or viral infection. Such a virus
can include, but is not limited to, Epstein Barr Virus (EBV).
Another embodiment of the invention relates to a method to treat or prevent a
disease or condition associated with Epstein Barr Virus (EBV) infection. The method
includes the step of administering to an individual any of the yeast-Brachyury
immunotherapeutic compositions described herein.
Yet r embodiment of the invention relates to a method to produce a
yeast-Brachyury immunotherapeutic ition. The method includes the steps of: (a)
culturing yeast that have been transformed with a recombinant nucleic acid molecule
encoding a Brachyury antigen under the control of a CUPI er in a suitable medium
in the absence of CuSO4 until the yeast reach mid-log growth phase; (b) inducing
expression of the Brachyury antigen in the yeast by adding CuSO4 to the medium; (c)
culturing the yeast after step (b) for up to between 6 and 8 hours; and (d) harvesting the
yeast. In one , the yeast in step (a) are ed to a cell density of between 1.0 and
2.0 Y.U. per milliliter total culture volume. In one aspect, the yeast in step (a) are ed
to a cell density of between 1.0 and 1.5 Y.U. per milliliter total e volume. In one
, the yeast are cultured in steps (a)-(c) in a medium where the pH is maintained at
pH 5.5 or higher. In one aspect, the method additionally includes a step of heat-
inactivating the yeast after step (d). For e, in one , the yeast are heat-
inactivated at about 56°C for about 1 hour. In a further aspect of this embodiment, the
yeast can be formulated for injection with a pharmaceutically acceptable excipient. In one
aspect, the yeast are from Saccharomyces. In one aspect, the yeast are from
Saccharomyces cerevisiae.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1A is a digitized image of a Western blot showing detection by anti-
Brachyury of expression of Brachyury in a yeast-Brachyury immunotherapeutic
composition, with both U2 and UL2 media.
Fig. 1B is a digitized image of a Western blot showing detection by anti-His of
expression of Brachyury in a yeast-Brachyury immunotherapeutic composition, with both
U2 and UL2 media.
Fig. 2 is a digitized image of a Western blot showing sion of Brachyury
in a yeast-Brachyury immunotherapeutic composition where the cell density at antigen
induction and the time to harvest after antigen induction were varied.
Figs. 3A-3C are graphs showing that peripheral blood mononuclear cells
) from two out of three healthy donors pulsed with yeast-Brachyury for two
cycles of stimulation, followed by pulsing with Brachyury CTL peptide, were capable of
generating CD8+ CTLs that could kill SW480 oma cells (HLA-A2
positive/Brachyury high), with minimal lysis of MCF7 carcinoma (HLA-A2
ve/Brachyury low); (Fig. 3A, donor 07706; Fig. 3B, donor 17663; Fig. 3C, donor
Fig. 4A is a graph showing that Brachyury-specific T cells from healthy donor
PBMCs stimulated with a yeast-Brachyury immunotherapeutic composition specifically
lyse tumor cells that have the appropriate MHC (SW480, HLA-A2 positive/Brachyury
high) versus H226 carcinoma cells (HLA-A2 negative/Brachyury high).
Fig. 4B is a graph g the expression of Brachyury mRNA relative to that
of a control gene (GAPDH) in the SW480 and H226 tumor cells used in the experiment
shown in Fig. 4A.
Fig. 5 is a graph showing proliferation of CD4+ T cells isolated from the
spleen of mice that were vaccinated with yeast-Brachyury (GI-6301, circles) or l
yeast (Yeast control, triangles), in response to indicated doses of purified Brachyury
protein or control B-gal protein.
Fig. 6 graph showing that stration of a yeast-Brachyury
immunotherapeutic composition (GI-6301, circles) of the invention shows a trend towards
reducing Brachyury-expressing tumors in mice compared to mice receiVing yeast alone
(no Brachyury antigen).
Figs. 7A and 7B are flow cytometry analyses showing that the Brachyuryspecif1c
T cell line, TBR-A, binds to a Brachyury-specific HLA-A2 tetramer (Fig. 7B)
and not to a l tetramer (Fig. 7A).
Fig. 8 is a flow cytometry analysis showing the expression of perforin in the
Brachyury-specific T cell line, TBR-A, after stimulation with Brachyury agonist
peptide-pulsed autologous B cells.
DETAILED DESCRIPTION OF THE INVENTION
This invention generally relates to based immunotherapeutic
compositions and methods for the prevention and/or ent of cancers that express or
overexpress Brachyury. The invention includes the use of a yeast-based
immunotherapeutic composition (also referred to as yeast-based immunotherapy)
comprising a yeast vehicle and Brachyury antigens or immunogenic domains thereof (also
ed to herein as “yeast-Brachyury immunotherapy” or “yeast-Brachyury
immunotherapeutic compositions”). The inventors describe herein the uction and
production of novel yeast-Brachyury immunotherapy products, and demonstrate that
yeast-Brachyury therapy expands Brachyury-specific T cells, including CD8+
CTLs, from normal individuals and from cancer ts. In addition, mice immunized
with yeast-Brachyury immunotherapeutic compositions generated Brachyury-specific T
cell responses in vivo, and ury-expressing tumor growth was inhibited in these mice.
Taken together, the data presented herein show that yeast-Brachyury therapy is
useful for the elicitation of Brachyury-specific cellular immune responses (CD4+ and
CD8+) and for the prevention and treatment of Brachyury-expressing tumors, offering
novel therapy for the prevention and/or treatment of metastatic cancers and associated
conditions.
Yeast-Brachyury immunotherapeutic compositions useful in the present
invention are uniquely adapted to effectively target Brachyury-expressing cancers for
several reasons. First, Brachyury is ed in EMT processes, and therefore, without
being bound by theory, the inventors believe that it plays a role in late-stage tumors and
atic processes. Accordingly, in one aspect of the invention, yeast-Brachyury
immunotherapy is effective at targeting tumor cells before or at the time during which they
begin to acquire ty and invade other s, thereby ting, inhibiting, arresting,
reversing or delaying the onset of metastatic cancer and/or the progression of , and
especially metastatic . There is a great need for effective therapies for late stage
cancers, especially metastatic cancers, which may have few options for treatment once
conventional cancer therapy has failed. Yeast-Brachyury presents a novel approach to
treat such s, or to delay, inhibit, reverse, or prevent them altogether. In addition,
yeast-Brachyury immunotherapy can be used to prevent or delay metastatic cancer or
progression of cancer in individuals who have early stage cancer. The therapy is useful, in
one embodiment, in s that have a high rate of metastatic progression, and may be
useful to arrest progression of the cancer. Furthermore, yeast-Brachyury immunotherapy
is useful in individuals who have a precancerous (pre-malignant) lesion or tumor, in
individuals who are at a high risk for developing a cancer, particularly one that has a high
rate of metastases, and even in normal individuals as a prophylactic agent for the
prevention of cancer, which may be used in conjunction with other lactic
immunotherapy for cancer, such as described herein.
Yeast-Brachyury therapy also provides a benefit to individuals who
are undergoing other therapy for cancer, including chemotherapy and radiation therapy.
More particularly, metastatic cancers are known in some cases to be more resistant to
chemotherapy and/or radiation therapy than the primary cancers. Therefore, the yeast-
ury immunotherapy itions of the invention can be used to inhibit or reduce
or eliminate chemotherapy resistance or radiation resistance that may occur in metastatic
cancer by inhibiting Brachyury expression in the cancer (and thereby inhibiting anti-
proliferative influences), and compositions of the invention may enhance the performance
of chemotherapy or radiation therapy in an individual.
Yeast-Brachyury immunotherapy can also be used to treat conditions or
diseases associated with Brachyury expression that may be non-oncological in nature, or
that may precede ant transformation. For example, Brachyury may be upregulated
in cells that are infected with an infectious agent, e.g., a Virus such as Epstein Barr Virus
(EBV). Accordingly, yeast-Brachyury immunotherapy can be used to treat or prevent any
disease or condition associated with Brachyury expression, including, but not limited to,
infectious diseases, such as Viral infection, including, but not limited to, sociated
conditions (e.g., mononucleosis).
Yeast-Brachyury immunotherapy is also readily ble to the use of
additional tumor antigens within the same yeast composition, or to use in combination
with other yeast-based therapeutics that target other tumor antigens (sequentially
or concurrently) or other immunotherapeutics and treatments/therapies for cancer.
ingly, the yeast-Brachyury immunotherapy can be adapted to the cancer type, the
cancer stage, the cancer grade, the antigens expressed by the tumor, and the l
medical status of the indiVidual (i.e., the therapy is easily personalized), and for the
individual who y has cancer, its use can be modified as cancer progresses in an
indiVidual, in order to provide maximum efficacy at a variety of tumor stages. Yeast-
ury therapy offers the opportunity to design sophisticated and effective,
individualized approaches for the based prophylactic and/or therapeutic treatment of
a wide range of cancers.
Yeast-Brachyury compositions described herein induce innate immune
responses, as well as adaptive immune responses against the target antigen (Brachyury),
including CD4-dependent THl7 and THl T cell responses and antigen-specific CD8+ T
cell responses, which include cytotoxic T lymphocyte (CTL) ses, all t the use
of exogenous nts, cytokines, or other immunostimulatory molecules, many of which
have toxicity issues. In addition, yeast-Brachyury immunotherapeutic compositions
inhibit tory T cell (Treg) numbers and/or functionality, thereby enhancing effector T
cell responses that might normally be suppressed by the presence of the tumor, for
example. Moreover, as compared to immunotherapeutic compositions that immunize by
generating antibody responses, the antigen-specific, broad-based, and potent cellular
immune responses elicited by yeast-Brachyury immunotherapy are believed to be
particularly effective in targeting tumor cells. Indeed, numerous studies have shown that
immunotherapeutic approaches are enhanced when tumor cells are targeted via CD8+
CTLs which recognize tumor peptides in the context ofMHC Class I molecules.
Yeast-Brachyury immunotherapy is highly adept at activating antigen
presenting cells, and has a unique y to cross-prime the immune response, generating
CD8+ CTL responses that are typically effective against tumors, even in the face of what
may otherwise be a suppressive nment. Since this type of immunotherapy utilizes
the natural ability of the antigen presenting cell to present relevant gens, it is not
necessary to know the precise identity of CTL es or MHC Class II epitopes of
Brachyury to produce an effective therapeutic ing to the present invention.
In fact, multiple CD4+ and CD8+ T cell epitopes can be targeted in a single yeast-
Brachyury immunotherapeutic composition, and so the yeast-Brachyury
immunotherapeutics of the invention are not limited to the use of short peptides and in fact,
the use of longer polypeptides and fusion proteins in these compositions is efficacious.
Accordingly, by using yeast-Brachyury immunotherapy, the use of thms and
complex formulas to identify ve T cell epitopes is eliminated.
Furthermore, since Brachyury is not expressed by most normal umor)
tissues, and is typically over-expressed in tumor cells, any “off target” s related to
normal tissues are not of concern. As mentioned above, yeast-Brachyury can be
ively utilized in an immunization protocol (prophylactic or therapeutic) without the
use of exogenous adjuvants, immunostimulatory agents or les, costimulatory
molecules, or nes, although such agents may be included, if desired. Moreover,
yeast-Brachyury immunotherapy can be administered repeatedly without losing efficacy,
as may be problematic with other types of immunotherapy.
Comgositl'ons 0: the Invention
One embodiment of the present invention relates to a yeast-based
immunotherapy composition which can be used to prevent and/or treat cancers
characterized by Brachyury expression or overexpression ding cancers that may not
contain cells expressing detectable ury initially, but which may or will contain cells
expressing Brachyury at later stages of the development of the cancer). The composition
is a yeast-Brachyury immunotherapeutic composition comprising: (a) a yeast vehicle; and
(b) a cancer antigen comprising one or more Brachyury antigen(s) and/or immunogenic
domain(s) thereof. The ury antigen or immunogenic domain thereof is most
typically expressed as a recombinant protein by the yeast vehicle (e.g., by an intact yeast
or yeast spheroplast, which can optionally be further processed to a yeast cytoplast, yeast
ghost, or yeast membrane t or fraction f), although it is an embodiment of the
invention that one or more Brachyury antigens are loaded into a yeast vehicle or otherwise
complexed with, ed to, mixed with or administered with a yeast vehicle as described
herein to form a composition of the present invention.
A “yeast-Brachyury immunotherapeutic composition” is a specific type of
“yeast-based immunotherapeutic composition3, that contains at least one Brachyury
antigen or immunogenic domain thereof. The phrase, -based immunotherapeutic
composition” may be used interchangeably with “yeast-based immunotherapy product”,
“yeast-based immunotherapy composition”, “yeast-based composition”, “yeast-based
immunotherapeutic”, “yeast-based vaccine”, or derivatives of these phrases. An
“immunotherapeutic ition” is a composition that elicits an immune response
sufficient to achieve at least one therapeutic benefit in a t. As used herein, yeast-
based immunotherapeutic composition refers to a composition that includes a yeast vehicle
component and that elicits an immune response sufficient to achieve at least one
eutic benefit in a subject. More ularly, a yeast-based immunotherapeutic
composition is a composition that includes a yeast vehicle component and typically, an
antigen component, and can elicit or induce an immune response, such as a cellular
immune se, including without limitation a T cell-mediated cellular immune
response. In one , a yeast-based immunotherapeutic composition useful in the
invention is capable of inducing a CD8+ and/or a CD4+ T cell-mediated immune response
and in one aspect, a CD8+ and a CD4+ T cell-mediated immune response, particularly
against a target antigen (e. g., a cancer antigen). A CD4+ immune response can include
THl immune responses, TH2 immune responses, THl7 immune responses, or any
combination of the above. based immunotherapeutics are particularly capable of
generating THl and THl7 responses. A CD8+ immune response can include a cytotoxic T
lymphocyte (CTL) response, and yeast-based immunotherapeutics are capable of
generating such responses. In one aspect, a yeast-based immunotherapeutic composition
modulates the number and/or functionality of regulatory T cells (Tregs) in a subject.
Yeast-based immunotherapy can also be d to promote one type of response over
another, e.g., by the addition of cytokines, antibodies, and/or modulating the
manufacturing process for the yeast. Optionally, a based immunotherapeutic
composition is capable of ing a humoral immune response.
Yeast-Brachyury therapeutic compositions of the invention may be
either "prophylactic" or "therapeutic". When provided prophylactically, the compositions
of the present invention are provided in advance of the development of, or the detection of
the development of, a cancer that expresses Brachyury, with the goal of preventing,
inhibiting or delaying the development of Brachyury-expressing tumors; and/or preventing,
inhibiting or delaying tumor migration and/or tumor invasion of other tissues (metastases)
and/or generally ting or inhibiting ssion of cancer in an individual. As
discussed herein, Brachyury is expressed in l cancers, ing late-stage cancers,
and has been shown to be involved in the EMT process, which is a process associated with
invasiveness and migration of tumors, such as in metastatic cancer. Therefore,
prophylactic compositions can be administered to individuals that appear to be cancer-free
(healthy, or normal, individuals), to individuals with pre-cancerous (pre-malignant lesions),
and also to individuals who have , but in which Brachyury has not yet been detected
(Le. prior to the expression of Brachyury by tumor cells in the cancer). Individuals who
are at high risk for developing a cancer, particularly a cancer with which Brachyury
expression and/or metastases are typically associated, may be treated prophylactically with
a composition of the invention. When ed therapeutically, the immunotherapy
compositions are provided to an individual with a Brachyury-expressing cancer, with the
goal of ameliorating the cancer, such as by reducing tumor burden in the individual;
inhibiting tumor growth in the individual; increasing survival of the individual; preventing,
inhibiting, reversing or delaying pment of tumor migration and/or tumor invasion of
other tissues (metastatic ) and/or preventing, inhibiting, reversing or delaying
progression of the cancer in the individual. In one , yeast-Brachyury
immunotherapy is used therapeutically to inhibit, reduce or eliminate chemotherapy
resistance or radiation resistance that may occur in metastatic cancer by inhibiting
Brachyury expression in the cancer, and compositions of the invention may enhance the
performance of chemotherapy or radiation therapy in an individual.
Typically, a Brachyury immunotherapy composition includes a yeast
vehicle and at least one cancer antigen comprising a Brachyury antigen or immunogenic
domain thereof, where the cancer antigen is expressed by, ed to, loaded into, or
mixed with the yeast vehicle. In some embodiments, the cancer antigen, Brachyury
n, or immunogenic domain thereof is provided as a fusion n. Several
Brachyury proteins and fusion ns suitable for use in the compositions and methods
of the invention are described below. In some embodiments, the cancer n and the
Brachyury antigen are the same element. In some embodiments, the cancer antigen
includes other antigens, including other cancer antigens, in addition to the ury
antigen. In one aspect of the invention, a fusion protein useful as a cancer n can
include two or more antigens, e.g., a Brachyury antigen and another cancer antigen that is
not a Brachyury antigen, or two different Brachyury antigens. In one aspect, the fusion
n can include two or more immunogenic domains of one or more antigens, such as
two or more immunogenic domains of a Brachyury antigen, or two or more epitopes of
one or more antigens, such as two or more epitopes of a Brachyury antigen.
According to the present ion, a yeast vehicle used in a yeast-Brachyury
immunotherapy composition is any yeast cell (e.g., a whole or intact cell) or a derivative
thereof (see below) that can be used in conjunction with one or more antigens,
immunogenic domains thereof or epitopes thereof in a ition of the invention (e.g.,
a therapeutic or prophylactic composition). The yeast vehicle can therefore include, but is
not limited to, a live intact (whole) yeast microorganism (i.e., a yeast cell having all its
components including a cell wall), a killed (dead) or inactivated intact yeast
rganism, or derivatives of intact yeast including: a yeast spheroplast (i.e., a yeast
cell lacking a cell wall), a yeast cytoplast (i.e., a yeast cell g a cell wall and nucleus),
a yeast ghost (i.e., a yeast cell lacking a cell wall, nucleus and cytoplasm), a subcellular
yeast membrane extract or fraction thereof (also ed to as a yeast ne particle
and previously as a subcellular yeast particle), any other yeast particle, or a yeast cell wall
preparation.
Yeast spheroplasts are typically produced by enzymatic digestion of the yeast
cell wall. Such a method is described, for example, in Franzusoff et al., 1991, Meth.
Enzymol. 194, 662-674., incorporated herein by reference in its entirety.
Yeast cytoplasts are typically produced by enucleation of yeast cells. Such a
method is described, for example, in Coon, 1978, Natl. Cancer Inst. Monogr. 48, 45-55
incorporated herein by reference in its ty.
Yeast ghosts are lly produced by resealing a permeabilized or lysed cell
and can, but need not, contain at least some of the organelles of that cell. Such a method
is bed, for example, in Franzusoff et al., 1983, J. Biol. Chem. 258, 3608-3614 and
Bussey et al., 1979, Biochim. Biophys. Acta 553, 185-196, each of which is incorporated
herein by reference in its entirety.
A yeast membrane particle (subcellular yeast ne extract or fraction
thereof) refers to a yeast ne that lacks a natural nucleus or cytoplasm. The particle
can be of any size, including sizes g from the size of a natural yeast membrane to
microparticles produced by sonication or other ne disruption methods known to
those d in the art, followed by resealing. A method for producing subcellular yeast
membrane extracts is described, for example, in Franzusoff et al., 1991, Meth. Enzymol.
194, 662-674. One may also use fractions of yeast membrane particles that contain yeast
membrane ns and, when the antigen or other protein was expressed recombinantly
by the yeast prior to preparation of the yeast membrane particles, the n or other
protein of interest. Antigens or other proteins of interest can be carried inside the
membrane, on either e of the membrane, or combinations thereof (i.e., the protein
can be both inside and outside the membrane and/or spanning the membrane of the yeast
membrane particle). In one embodiment, a yeast membrane particle is a recombinant
yeast membrane particle that can be an intact, disrupted, or disrupted and resealed yeast
membrane that includes at least one desired antigen or other protein of interest on the
surface of the membrane or at least partially embedded within the ne.
An example of a yeast cell wall preparation is a preparation of isolated yeast
cell walls carrying an antigen on its surface or at least partially embedded within the cell
wall such that the yeast cell wall preparation, when administered to an animal, stimulates a
desired immune response against a disease .
Any yeast strain can be used to produce a yeast vehicle of the present
invention. Yeast are unicellular microorganisms that belong to one of three classes:
Ascomycetes, Basidiomycetes and Fungi Imperfecti. One consideration for the ion
of a type of yeast for use as an immune modulator is the pathogenicity of the yeast. In one
embodiment, the yeast is a non-pathogenic strain such as Saccharomyces cerevisiae. The
selection of a thogenic yeast strain minimizes any adverse effects to the dual
to whom the yeast vehicle is administered. However, pathogenic yeast may be used if the
pathogenicity of the yeast can be negated by any means known to one of skill in the art
(e.g., mutant strains). In accordance with one aspect of the present invention, non-
enic yeast strains are used.
Genera of yeast strains that may be used in the invention include but are not
limited to Saccharomyces, Candida (which can be pathogenic), Cryptococcus, Hansemda,
romyces, Pichia, Rhodotorula, Schizosaccharomyces and Yarrowz'a. In one aspect,
yeast genera are selected from Saccharomyces, Candida, Hansemda, Pichia or
Schizosaccharomyces, and in one aspect, Saccharomyces is used. Species of yeast strains
that may be used in the invention include but are not d to Saccharomyces cerevisiae,
Saccharomyces carlsbergensis, Candida albicans, Candida kefyr, Candida tropicalis,
Cryptococcus laurentii, Cryptococcus neoformans, Hansenula anomala, Hansenula
rpha, Kluyveromycesfragilis, Kluyveromyces lactis, Kluyveromyces marxianus var.
lactis, Pichia pastoris, Rhodotorula rubra, Schizosaccharomyces pombe, and Yarrowia
lipolytica. It is to be appreciated that a number of these species include a variety of
subspecies, types, subtypes, etc. that are ed to be included within the
aforementioned species. In one aspect, yeast species used in the invention include S.
cerevisiae, C. albicans, H. polymorpha, P. pastoris and S. pombe. S. cerevisiae is useful
as it is relatively easy to manipulate and being "Generally Recognized As Safe" or
"GRAS" for use as food additives (GRAS, FDA proposed Rule 62FR18938, April 17,
1997). One embodiment of the t invention is a yeast strain that is capable of
replicating plasmids to a particularly high copy number, such as a S. cerevisiae cir° strain.
The S. siae strain is one such strain that is capable of supporting expression vectors
that allow one or more target antigen(s) and/or antigen fusion protein(s) and/or other
proteins to be expressed at high levels. r yeast strain is useful in the invention is
Saccharomyces cerevisiae W303 or. In addition, any mutant yeast strains can be used in the
present invention, including those that exhibit reduced post-translational modifications of
expressed target antigens or other proteins, such as ons in the enzymes that extend
N—linked glycosylation.
The yeast-Brachyury immunotherapy composition of the invention includes at
least one cancer antigen comprising a ury antigen. ing to the present
invention, the general use herein of the term "antigen" : to any n of a protein
(e.g., e, l protein, full-length protein), wherein the protein is lly
occurring or synthetically derived or designed, to a cellular composition (whole cell, cell
lysate or ted cells), to an organism (whole organism, lysate or disrupted cells) or to a
carbohydrate, or other le, or a portion thereof. An antigen may elicit an antigenspecific
immune response (e. g., a humoral and/or a cell-mediated immune response)
against the same or similar antigens that are encountered by an element of the immune
system (e.g., T cells, antibodies).
An antigen can be as small as a single epitope, a single immunogenic domain
or larger, and can include multiple epitopes or immunogenic domains. As such, the size of
an antigen can be as small as about 8-11 amino acids (i.e., a peptide) and as large as: a full
length protein, a multimer, a fusion protein, a chimeric protein, a Whole cell, a Whole
microorganism, or any portions thereof (e.g., protein nts (polypeptides) s of
Whole cells or extracts of microorganisms). ns useful in the yeast-Brachyury
immunotherapeutic of the present invention are peptides, polypeptides, full-length proteins,
multimers, fusion proteins and chimeric proteins. In addition, antigens can include
carbohydrates, Which can be loaded into a yeast vehicle or into a composition of the
invention. It Will be appreciated that in some embodiments (e.g., When the n is
expressed by the yeast vehicle from a inant nucleic acid molecule), the antigen is a
protein, fusion protein, chimeric protein, or fragment thereof, rather than an entire cell or
microorganism. For expression in yeast, an antigen is of a minimum size capable of being
expressed recombinantly in yeast if the antigen is the entire protein to be expressed by the
yeast, and is lly at least or greater than 25 amino acids in length, or at least or greater
than 26, at least or greater than 27, at least or greater than 28, at least or greater than 29, at
least or greater than 30, at least or greater than 31, at least or greater than 32, at least or
greater than 33, at least or greater than 34, at least or r than 35, at least or greater
than 36, at least or greater than 37, at least or greater than 38, at least or greater than 39, at
least or greater than 40, at least or greater than 41, at least or greater than 42, at least or
greater than 43, at least or greater than 44, at least or greater than 45, at least or greater
than 46, at least or greater than 47, at least or r than 48, at least or greater than 49, or
at least or greater than 50 amino acids in length, or at least or greater than 25-50 amino
acids in length, or at least or greater than 30-50 amino acids in length, or at least or greater
than 35-50 amino acids in length, or at least or greater than 40-50 amino acids in length, or
at least or greater than 45-50 amino acids in length, although smaller proteins may be
expressed, and considerably larger ns (e.g., hundreds of amino acids in length or
even a few thousand amino acids in length) may be expressed. In one aspect, a ength
protein or a protein that is lacking between 1 and 20 amino acids from the N— and/or the C-
terminus may be expressed. Fusion ns and chimeric ns are also antigens that
may be expressed in the invention. A “target antigen” is an antigen that is specifically
targeted by an immunotherapeutic composition of the invention (i.e., an antigen against
Which elicitation of an immune response is desired). A “cancer antigen” is an antigen that
comprises at least one antigen that is associated With a cancer such as an antigen expressed
by a tumor cell, such that ing the antigen also s the cancer. A cancer antigen
can include one or more antigens from one or more proteins, including one or more tumor-
associated proteins. A “Brachyury antigen” is an antigen derived, designed, or produced
from a Brachyury protein.
When referring to stimulation of an immune response, the term “immunogen”
is a subset of the term “antigen”, and therefore, in some instances, can be used
interchangeably with the term "antigen". An gen, as used herein, describes an
antigen which elicits a humoral and/or cell-mediated immune response (i.e., is
immunogenic), such that administration of the immunogen to an individual mounts an
antigen-specific immune response against the same or similar antigens that are
encountered by the immune system of the dual. In one embodiment, the immunogen
elicits a cell-mediated immune response, including a CD4+ T cell response (e.g., THl,
TH2 and/or THl7) and/or a CD8+ T cell response (e.g., a CTL response).
An “immunogenic domain” of a given antigen can be any portion, fragment or
e of an antigen (e.g., a peptide fragment or subunit or an antibody epitope or other
mational epitope) that contains at least one epitope that can act as an immunogen
when administered to an animal. Therefore, an immunogenic domain is larger than a
single amino acid and is at least of a size sufficient to n at least one epitope that can
act as an immunogen. For example, a single protein can contain le ent
immunogenic domains. Immunogenic domains need not be linear sequences within a
protein, such as in the case of a humoral immune response, where conformational domains
are contemplated.
An epitope is defined herein as a single immunogenic site within a given
antigen that is sufficient to elicit an immune response when provided to the immune
system in the context of riate costimulatory signals and/or ted cells of the
immune system. In other words, an epitope is the part of an n that is recognized by
components of the immune system, and may also be referred to as an antigenic
determinant. Those of skill in the art will recognize that T cell epitopes are different in
size and composition from B cell or antibody epitopes, and that epitopes presented h
the Class I MHC pathway differ in size and structural utes from epitopes presented
through the Class II MHC pathway. For example, T cell epitopes presented by Class I
MHC molecules are typically between 8 and 11 amino acids in length, whereas epitopes
presented by Class II MHC molecules are less restricted in length and may be up to 25
amino acids or longer. In addition, T cell epitopes have predicted structural characteristics
depending on the specific MHC molecules bound by the epitope. Epitopes can be linear
sequence epitopes or conformational epitopes (conserved binding regions). Most
antibodies recognize mational epitopes.
Brachyury (which may also be referred to as “T”) is a highly conserved
protein among multiple different animal species and is a transcription factor that contains a
“T-box” domain or “T-domain”, a DNA-binding domain motif shared among several
ent proteins, collectively called the T-box family of proteins. Human Brachyury was
first cloned in 1996 (Edwards et al., supra). One nucleotide sequence encoding human
Brachyury is represented herein by SEQ ID NO:l, which is an mRNA sequence that was
obtained from GENBANK® Accession No. NM_003l8l (GI:l97438l l). SEQ ID NO:l
encodes a 435 amino acid human Brachyury protein, the amino acid ce of which is
represented here as SEQ ID NO:2 (also found in GENBANK® Accession No. NP_003 172;
GI:4507339).
Another human Brachyury protein disclosed herein is a variant of the human
Brachyury protein represented by SEQ ID N02, and has the amino acid sequence of SEQ
ID NO:6. SEQ ID NO:6, also a 435 amino acid protein, is encoded by a tide
sequence represented herein by SEQ ID NO:5. SEQ ID NO:6 is approximately 99%
identical to SEQ ID NO:2 over the full-length of the protein. SEQ ID NO:6 differs from
SEQ ID NO:2 at position 177 (Asp vs. Gly, respectively), position 368 (Thr vs. Ser,
respectively) and position 409 (Asn vs. Asp, respectively).
Another human Brachyury protein disclosed herein is an agonist of the human
Brachyury protein represented by SEQ ID N02 or SEQ ID NO:6. As generally used
herein, an “agonist” is any compound or agent, including without tion small
molecules, proteins, es, antibodies, nucleic acid binding agents, etc., that binds to a
receptor or ligand and produces or rs a response, which may include agents that
mimic or enhance the action of a naturally occurring substance that binds to the receptor or
ligand. When used in the context of a ury antigen of the invention, an “agonist”
antigen or protein refers to an antigen or protein that ses at least one T cell agonist
e, which may also be referred to as a “mimotope”. A mimotope peptide is a peptide
that mimics the structure of a wild-type epitope and as an agonist, the mimotope mimics or
enhances the action (biological function) of the natural e. For example, the amino
acid ce of SEQ ID NO:12 (WLLPGTSTL) is a T cell epitope of a wild-type
Brachyury protein. The amino acid sequence of SEQ ID NOil3 (WLLPGTSTV) is a
mimotope or t of the T cell epitope of SEQ ID NO: 12.
One human ury agonist n is represented here by SEQ ID NO:l8.
SEQ ID NO:l8 is a 435 amino acid protein is encoded by a nucleotide sequence
represented herein by SEQ ID NO:l7. SEQ ID NO:l8 is identical to SEQ ID NO:6,
except for a substitution of a e at position 254 with respect to SEQ ID NO:6 with a
valine in SEQ ID NO:l8. This substitution creates a T cell agonist epitope in SEQ ID
NO:l8 at positions 246 to 254 that, without being bound by theory, is ed to induce
enhanced T cell responses against Brachyury as compared to the wild-type epitope
(positions 246 to 254 of SEQ ID NO:6).
Positions 41 to 223 of any of SEQ ID NO:2, SEQ ID NO:6 or SEQ ID NO:l8
represent the T-box DNA binding domain of human ury, and the T-box domain in
other Brachyury sequences, including Brachyury sequences from other species, can be
readily identified by comparison to these sequences. As used herein, reference to a T-box
domain of any Brachyury protein described herein or known in the art and utilized in the
ion may include an additional 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, ll, l2, l3, l4, l5, l6, l7,
l8, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40
utive amino acids of the Brachyury sequence on the N—terminal and/or the C-
terminal end of the defined T-box domain (e.g., on either side of positions 41-223 of SEQ
ID NOs:2, 6 or 18). Human Brachyury, including the two human Brachyury ns
described herein, also contains various CD4+ and CD8+ T cell epitopes. Such epitopes
have been described, for example, in WC 2008/106551, and include a CD8+ CTL epitope,
WLLPGTSTL (also referred to herein as Tp2, SEQ ID NO:l2), at positions 246 to 254 of
SEQ ID NO:2 or SEQ ID NO:6. As discussed above, SEQ ID NO:l8 comprises an
agonist epitope of SEQ ID NO: 12, represented herein by SEQ ID NO: 13.
Human Brachyury has very high homology with Brachyury from other animal
species and therefore, one is able to utilize the sequences of Brachyury from other
organisms in the preparation of a yeast-Brachyury immunotherapeutic composition of the
invention, particularly where these sequences are identical, substantially homologous, and
elicit an ive immune se against the target antigen (e.g., native Brachyury
expressed by a tumor cell). For example, murine Brachyury, which was first cloned by
Hermann and colleagues in l990 nn et al., supra) is approximately 85% identical
to human ury at the nucleotide level, and approximately 91% identical at the amino
acid level. With respect to Brachyury from other animals, at the amino acid level, human
Brachyury is 99.5% identical to Brachyury from Pan troglodytes, 90.1% identical to
Brachyury from Cam's lupus familiaris, 88.5% identical to Brachyury from Bos Taurus,
92.2% identical to Brachyury from Rattus icus, and 80.9% identical to Brachyury
from Gallus gallus. Within amino acids 1-223 of Brachyury, which contains the T-box
domain, mouse and human Brachyury differ by only two amino acids (at positions 26 and
96). A nucleotide sequence encoding murine ury is represented herein by SEQ ID
NO:3, which is an mRNA sequence that was obtained from GENBANK® Accession No.
NM_009309 (GI:ll8l30357). SEQ ID NO:3 encodes a 436 amino acid murine Brachyury
protein, the amino acid ce of which is represented here as SEQ ID NO:4. Positions
41 to 223 of SEQ ID NO:4 represent the T-box DNA binding domain of murine
Brachyury.
In one embodiment of the invention, a Brachyury antigen comprises or
consists of the amino acid sequence represented by SEQ ID NO:2, SEQ ID NO:4, SEQ ID
NO:6, SEQ ID NO:l8, or at least one immunogenic domain thereof. In one embodiment,
a Brachyury antigen ses or consists of two, three, four, five, or more immunogenic
domains of Brachyury. In one embodiment of the invention, a Brachyury antigen
comprises or consists of the amino acid sequence represented by amino acid positions 1 or
2 through one of the last 25 amino acids at the C-terminus of SEQ ID NO:2, SEQ ID NO:4,
SEQ ID NO:6 or SEQ ID NO:l8 (1'. 6., through any one of positions 441 to 435 of SEQ ID
NO:2 or SEQ ID NO:6 or SEQ ID NO:l8, or h any one of positions 442 to 436 of
SEQ ID NO:4). Another Brachyury antigen useful in the invention also includes at least
amino acid positions 1-223 of Brachyury (e.g., ons 1-223 of SEQ ID NO:2, SEQ ID
NO:4, SEQ ID NO:6 or SEQ ID NO:l8) or ons 41-223 of Brachyury (e.g., positions
41-223 of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:l8). Another
Brachyury n useful in the invention includes from at least amino acid positions 1 to
85 to between position 255 and the C-terminus of SEQ ID NO:2, SEQ ID NO:4, SEQ ID
NO:6 or SEQ ID NO: 1 8. Another Brachyury antigen useful in the invention includes from
at least amino acid positions 1 to 85 to between on 430 and the C-terminus of SEQ
ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:l8. Another Brachyury antigen
useful in the invention includes from at least amino acid positions 1, 2, 3, 4, 5, 6, 7, 8, 9 or
to n position 255 and the C-terminus of SEQ ID NO:2, SEQ ID NO:4, SEQ ID
NO:6 or SEQ ID NO:l8.
According to any ment of the present ion, reference to a “full-
length” protein (or a full-length functional domain or full-length immunological domain)
includes the full-length amino acid sequence of the protein or functional domain or
immunological domain, as described herein or as otherwise known or described in a
publicly available sequence. A protein or domain that is “near full-length”, which is also a
type of homologue of a protein, s from a full-length protein or domain, by the
addition or deletion or omission of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids from the N-
and/or C-terminus of such a full-length protein or ength domain. By way of example,
several of the fusion proteins described herein comprise a “near full-length” Brachyury
antigen since the antigen omits the methionine at position 1 and substitutes an N—terminal
peptide. General reference to a protein or domain or antigen can include both ength
and near full-length proteins, as well as other homologues thereof.
In one aspect of any embodiments related to a Brachyury antigen, a cancer
antigen or a Brachyury antigen is of a minimum size sufficient to allow the antigen to be
expressed by yeast. For expression in yeast, a protein is typically at least about 25 amino
acids in length, although smaller ns may be expressed, and considerably larger
proteins may be expressed by yeast. For example, a Brachyury antigen useful in the
invention is a fragment of a Brachyury protein that can be expressed recombinantly by
yeast and that contains at least one immunogenic domain of Brachyury, which could
include at least one genic domain of any of SEQ ID NO:2, SEQ ID NO:4, SEQ ID
NO:6 or SEQ ID NO:18. In one aspect, such an antigen is at least 25 amino acids in
length, and contains at least one immunogenic domain of Brachyury. In one aspect, such
an antigen is r than 30 amino acids in length, and contains at least one immunogenic
domain of Brachyury. In one aspect, such an antigen is at least 25-50 amino acids in
length, and contains at least one immunogenic domain of Brachyury. In one aspect, such
an antigen is at least 30-50 amino acids in length, and contains at least one immunogenic
domain of Brachyury. In one aspect, such an antigen is at least 35-50 amino acids in
length, and contains at least one immunogenic domain of Brachyury. In one aspect, such
an antigen is at least 40-50 amino acids in length, and contains at least one genic
domain of Brachyury. In one aspect, such an antigen is at least 45-50 amino acids in
length, and ns at least one immunogenic domain of ury. In one ment,
the Brachyury antigen useful in the present ion is at least 25 amino acids in length,
or at least: 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120,
125,130,135,140,145,150,155,160,165,170,175,180,185,190,195,200,205,210,
215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300,
305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390,
395, 400, 405, 410, 415, 420, 425, or 430 amino acids in length, which can include any
fragment of at least any of these lengths of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or
SEQ ID NO: 1 8.
In one aspect, a Brachyury antigen comprises one or more CTL epitopes,
Which may include two or more copies of any one, two, three, or more of the CTL
epitopes described herein. In one aspect, the Brachyury antigen comprises one or more
CD4+ T cell epitopes. The T cell In one aspect, the Brachyury antigen comprises one or
more CTL epitopes and one or more CD4+ T cell epitopes. In one aspect, the T cell
epitope is an agonist epitope.
In one aspect, a Brachyury antigen comprises an amino acid sequence of
WLLPGTSTL (SEQ ID NO:l2, also represented by positions 245 to 254 of SEQ ID N02
or SEQ ID NO:6). In one aspect, the Brachyury n comprises an amino acid
sequence of WLLPGTSTV (SEQ ID NO:l3, also ented by positions 245 to 254 of
SEQ ID NO:l8). In one aspect, the amino acid at position 4 of either SEQ ID NO:l2 or
SEQ ID NO:13 (a proline or P in these sequences) is substituted With a serine (S), a
threonine (T), an isoleucine (I), or a valine (V).
In one aspect, the Brachyury antigen comprises an amino acid ce of
SQYPSLWSV (SEQ ID NO:l4). In one , the amino acid at position 2 of SEQ ID
NO:14 (a glutamine or Q in this ce) is substituted With a leucine (L). In one aspect,
the amino acid at position 4 of SEQ ID NO:l4 (a proline or P in this sequence) is
substituted With a serine (S), threonine (T), e (L), or valine (V). In one aspect, the
amino acid at position 7 of SEQ ID NO:l4 (a tryptophan or W in this ce) is
substituted With a valine (V), leucine (L), isoleucine (I), serine (S), or threonine (T). In
one aspect, the amino acid at on 9 of SEQ ID NO: 14 (a valine or V in this sequence)
is tuted With a e (L). An antigen comprising a sequence haVing any
combination of one or more of these substitutions in SEQ ID NO:l4 is contemplated by
the invention.
In one aspect, the Brachyury antigen comprises an amino acid sequence of
RLIASWTPV (SEQ ID NO:l5). In one aspect, the amino acid at position 1 of SEQ ID
NO:15 (an arginine or R in this sequence) is substituted With a tyrosine (Y) or a
tryptophan (W). In one aspect, the amino acid at on 6 of SEQ ID NO:15 (a
tryptophan or W in this sequence) is substituted With a valine (V), a lysine (L), an
isoleucine (I), a serine (S), or a threonine (T). An antigen comprising a sequence haVing
any combination of one or both of these substitutions in SEQ ID NO:15 is contemplated
by the invention.
In one aspect, the Brachyury antigen comprises an amino acid sequence of
AMYSFLLDFV (SEQ ID NO:l6). In one aspect, the amino acid at position 2 of SEQ ID
NO: 16 (a methionine or M in this sequence) is substituted with a leucine (L).
In one embodiment of the invention, a Brachyury antigen comprises, consists
essentially of, or consists of a fusion protein having the amino acid sequence of SEQ ID
NO:8. The fusion protein of SEQ ID NO:8 is a single ptide with the following
sequence elements fused in frame from N— to C-terminus: (1) an N—terminal peptide to
impart resistance to proteasomal degradation and stabilize expression in yeast (positions 1-
6 of SEQ ID NO:8); (2) a human ury antigen consisting of positions 2-435 of SEQ
ID NO:6 (positions 7-440 of SEQ ID NO:8); and (3) a hexahistidine tag ions 441-
446 of SEQ ID NO:8). The amino acid sequence of SEQ ID NO:8 is encoded by the
polynucleotide sequence of SEQ ID NO:7.
In another embodiment of the invention, a Brachyury antigen comprises,
ts ially of, or consists of a fusion protein having the amino acid ce of
SEQ ID NOilO. The fusion protein of SEQ ID NO:lO is a single polypeptide with the
following sequence elements fused in frame from N- to C-terminus: (1) an N—terminal
peptide to impart ance to somal degradation and stabilize expression in yeast
(positions 1-6 of SEQ ID NO:lO); (2) a murine Brachyury antigen consisting of positions
2-436 of SEQ ID NO:4 (positions 7-441 of SEQ ID NO:lO); and (3) a hexahistidine tag
(positions 442-447 of SEQ ID NO:10). The amino acid sequence of SEQ ID NO:lO is
encoded by the polynucleotide sequence of SEQ ID NO:9.
In another embodiment of the invention, a Brachyury antigen comprises,
consists essentially of, or consists of a fusion protein having the amino acid ce of
SEQ ID NO:20. The fusion protein of SEQ ID NO:20 is a single polypeptide with the
following sequence elements fused in frame from N- to C-terminus: (1) an N—terminal
peptide to impart resistance to somal degradation and stabilize expression (positions
1 to 6 of SEQ ID NO:20, the peptide sequence also represented herein by SEQ ID NO: 1 l);
2) amino acids 2-435 of SEQ ID NO:l8 (positions 7-440 of SEQ ID NO:20), SEQ ID
NO:l8 representing a full-length human Brachyury agonist protein; and (3) a hexahistidine
tag (positions 441-446 of SEQ ID NO:20). The agonist epitope (SEQ ID NO:l3) is
located at ons 251 to 259 of SEQ ID NO:20 (positions 246 to 254 of SEQ ID NO:l8).
The amino acid ce of SEQ ID NO:20 is encoded by the polynucleotide sequence of
SEQ ID NO: 19.
A Brachyury antigen useful in the present invention also includes proteins
having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of
any of the Brachyury proteins or antigens described herein over the full length of the
protein, or with t to a defined fragment or domain thereof (e.g., an immunological
domain or onal domain (domain with at least one biological ty)) that forms part
of the protein. For e, a domain of the Brachyury protein bed herein includes
the T-box domain. An immunological domain has been described in detail above.
In some s of the invention, amino acid insertions, deletions, and/or
substitutions can be made for one, two, three, four, five, six, seven, eight, nine, ten, or
more amino acids of a wild-type or reference Brachyury protein, provided that the
resulting Brachyury n, when used as an antigen in a yeast-Brachyury
immunotherapeutic composition of the invention, elicits an immune response against a
native Brachyury protein as the wild-type or reference Brachyury protein, which may
include an enhanced immune response, a shed immune response, or a substantially
r immune response. For example, the invention includes the use of Brachyury
agonist antigens, which may include one or more T cell epitopes that have been mutated to
enhance the T cell response against the Brachyury t, such as by improving the
y or affinity of the epitope for an MHC molecule or for the T cell receptor that
recognizes the epitope in the t of MHC presentation. Brachyury agonists may
therefore improve the potency or efficiency of a T cell response t native Brachyury
expressed by a tumor cell. The Brachyury antigen haVing the amino acid sequence of
SEQ ID NO:l8 is a non-limiting e of a Brachyury agonist (or a Brachyury antigen
comprising an agonist epitope).
In addition, N—terminal expression sequences and the C-terminal tags, such as
those described above with respect to the fusion proteins of SEQ ID NO:8, SEQ ID NO: 10,
or SEQ ID NO:20 are optional, but may be ed from several different sequences
described elsewhere herein to improve or assist with expression, stability, and/or allow for
identification and/or purification of the protein. Also, many different promoters suitable
for use in yeast are known in the art. Furthermore, short intervening linker sequences (e.g.,
l, 2, 3, 4, or 5 amino acid peptides) may be introduced between portions of a fusion
protein comprising a Brachyury antigen for a variety of reasons, including the introduction
of restriction enzyme sites to facilitate cloning, as cleavage sites for host phagosomal
proteases, to accelerate n or antigen processing, and for future manipulation of the
constructs.
Optionally, proteins, including fusion proteins, which are used as a component
of the yeast-Brachyury immunotherapeutic ition of the invention are produced
using antigen constructs that are ularly useful for improving or stabilizing the
expression of heterologous antigens in yeast. In one embodiment, the desired antigenic
protein(s) or peptide(s) are fused at their terminal end to: (a) a specific synthetic
e that stabilizes the sion of the fusion protein in the yeast vehicle or prevents
posttranslational modification of the expressed fusion protein (such peptides are described
in detail, for e, in US. Patent Publication No. 2004-0156858 Al, published August
12, 2004, incorporated herein by reference in its entirety); (b) at least a portion of an
endogenous yeast protein, including but not limited to yeast alpha factor leader sequence,
wherein either fusion r provides improved ity of expression of the protein in
the yeast and/or a prevents post-translational modification of the proteins by the yeast cells
(such proteins are also described in , for example, in US. Patent Publication No.
2004-0156858 Al, supra); and/or (c) at least a portion of a yeast protein that causes the
fusion n to be expressed on the surface of the yeast (e.g., an Aga protein, described
in more detail herein). In addition, the present invention optionally includes the use of
peptides that are fused to the C-terminus of the antigen-encoding construct, particularly for
use in the selection and identification of the protein. Such peptides include, but are not
limited to, any synthetic or natural peptide, such as a peptide tag (e.g., 6X His or
hexapeptide) or any other short e tag. es attached to the C-terminus of an
antigen according to the ion can be used with or without the addition of the N-
terminal peptides discussed above, and vice versa.
In one embodiment, a synthetic peptide useful in a fusion protein to be
expressed in a yeast is linked to the N—terminus of the antigen, the peptide consisting of at
least two amino acid positions that are heterologous to the antigen, wherein the peptide
stabilizes the expression of the fusion protein in the yeast vehicle or prevents
posttranslational modification of the expressed fusion protein. The synthetic peptide and
N—terminal portion of the antigen together form a fusion protein that has the following
requirements: (1) the amino acid e at position one of the fusion protein is a
methionine (z'.e., the first amino acid in the synthetic peptide is a methionine); (2) the
amino acid residue at position two of the fusion protein is not a glycine or a proline (i.e.,
the second amino acid in the synthetic peptide is not a glycine or a proline); (3) none of
the amino acid positions at positions 2-6 of the fusion protein is a methionine (i.e., the
amino acids at positions 2-6, r part of the synthetic peptide or the protein, if the
synthetic peptide is shorter than 6 amino acids, do not include a methionine); and (4) none
of the amino acids at positions 2-6 of the fusion protein is a lysine or an arginine (i.e., the
amino acids at positions 2-6, whether part of the synthetic peptide or the protein, if the
tic peptide is shorter than 5 amino acids, do not include a lysine or an arginine).
The synthetic peptide can be as short as two amino acids, but in one , is 2-6 amino
acids (including 3, 4, 5 amino acids), and can be longer than 6 amino acids, in whole
integers, up to about 200 amino acids, 300 amino acids, 400 amino acids, 500 amino acids,
or more.
In one embodiment, a fusion protein comprises an amino acid sequence of M-
X2-X3-X4-X5-X6, n M is methionine; wherein X2 is any amino acid except
e, proline, lysine or arginine; wherein X3 is any amino acid except methionine,
lysine or ne; wherein X4 is any amino acid except methionine, lysine or arginine;
wherein X5 is any amino acid except methionine, lysine or arginine; and wherein X6 is
any amino acid except methionine, lysine or arginine. In one embodiment, the X6 residue
is a proline. An exemplary synthetic sequence that enhances the stability of expression of
an antigen in a yeast cell and/or prevents post-translational modification of the protein in
the yeast includes the sequence M-A-D-E-A-P (represented herein by SEQ ID NO:11). In
addition to the ed stability of the expression product, this fusion r does not
appear to vely impact the immune response against the immunizing antigen in the
construct. In on, the synthetic fusion peptides can be designed to provide an epitope
that can be ized by a selection agent, such as an antibody.
In one aspect of the invention, the yeast vehicle is manipulated such that the
n is expressed or provided by delivery or translocation of an expressed protein
product, partially or wholly, on the surface of the yeast vehicle (extracellular expression).
One method for accomplishing this aspect of the invention is to use a spacer arm for
positioning one or more protein(s) on the surface of the yeast vehicle. For example, one
can use a spacer arm to create a fusion protein of the antigen(s) or other protein of interest
with a protein that targets the n(s) or other protein of interest to the yeast cell wall.
For example, one such protein that can be used to target other proteins is a yeast protein
(e.g., cell wall protein 2 (cwp2), Aga2, Pir4 or Flol protein) that enables the antigen(s) or
other protein to be targeted to the yeast cell wall such that the antigen or other protein is
located on the surface of the yeast. Proteins other than yeast proteins may be used for the
spacer arm; however, for any spacer arm n, it is most desirable to have the
immunogenic response be directed against the target antigen rather than the spacer arm
protein. As such, if other proteins are used for the spacer arm, then the spacer arm protein
that is used should not generate such a large immune response to the spacer arm protein
itself such that the immune response to the target antigen(s) is overwhelmed. One of skill
in the art should aim for a small immune response to the spacer arm protein relative to the
immune response for the target antigen(s). Spacer arms can be constructed to have
cleavage sites (e.g., protease cleavage sites) that allow the antigen to be readily removed
or processed away from the yeast, if desired. Any known method of determining the
magnitude of immune responses can be used (e.g., antibody production, lytic assays, etc.)
and are readily known to one of skill in the art.
Another method for positioning the target antigen(s) or other proteins to be
exposed on the yeast surface is to use signal sequences such as glycosylphosphatidyl
inositol (GPI) to anchor the target to the yeast cell wall. Alternatively, positioning can be
accomplished by appending signal sequences that target the antigen(s) or other proteins of
interest into the secretory pathway Via translocation into the asmic reticulum (ER)
such that the antigen binds to a protein which is bound to the cell wall (e.g., cwp).
In one , the spacer arm protein is a yeast protein. The yeast protein can
consist of between about two and about 800 amino acids of a yeast protein. In one
embodiment, the yeast protein is about 10 to 700 amino acids. In another embodiment, the
yeast protein is about 40 to 600 amino acids. Other embodiments of the invention include
the yeast protein being at least 250 amino acids, at least 300 amino acids, at least 350
amino acids, at least 400 amino acids, at least 450 amino acids, at least 500 amino acids, at
least 550 amino acids, at least 600 amino acids, or at least 650 amino acids. In one
embodiment, the yeast protein is at least 450 amino acids in . r consideration
for optimizing antigen surface sion, if that is desired, is r the antigen and
spacer arm ation should be expressed as a monomer or as dimer or as a trimer, or
even more units ted together. This use of monomers, dimers, s, etc. allows
for appropriate spacing or folding of the antigen such that some part, if not all, of the
antigen is displayed on the surface of the yeast vehicle in a manner that makes it more
immunogenic.
Use of yeast proteins can stabilize the expression of fusion proteins in the
yeast vehicle, prevents posttranslational modification of the expressed fusion protein,
and/or targets the fusion protein to a ular compartment in the yeast (e.g., to be
expressed on the yeast cell surface). For ry into the yeast ory pathway,
exemplary yeast proteins to use include, but are not limited to: Aga (including, but not
limited to, Agal and/or Aga2); SUC2 (yeast invertase); alpha factor signal leader
sequence; CPY; pr2p for its localization and retention in the cell wall; BUD genes for
localization at the yeast cell bud during the initial phase of daughter cell formation; Flolp;
Pir2p; and Pir4p.
Other ces can be used to target, retain and/or stabilize the protein to
other parts of the yeast vehicle, for example, in the cytosol or the mitochondria or the
endoplasmic reticulum or the nucleus. Examples of suitable yeast protein that can be used
for any of the embodiments above include, but are not limited to, TK, AF, SEC7;
phosphoenolpyruvate carboxykinase PCKl, phosphoglycerokinase PGK and triose
phosphate isomerase TPI gene products for their repressible expression in glucose and
cytosolic localization; the heat shock proteins SSAl, SSA3, SSA4, SSCl, whose
expression is induced and whose proteins are more thermostable upon exposure of cells to
heat treatment; the mitochondrial protein CYCl for import into mitochondria; ACTl.
Methods of producing yeast vehicles and expressing, combining and/or
associating yeast vehicles with antigens and/or other ns and/or agents of st to
produce yeast-based immunotherapy compositions are contemplated by the invention.
According to the present ion, the term "yeast vehicle-antigen complex"
or "yeast-antigen complex" is used cally to describe any association of a yeast
vehicle with an n, and can be used interchangeably with “yeast-based
immunotherapy composition” when such ition is used to elicit an immune response
as described above. Such association includes expression of the antigen by the yeast (a
recombinant yeast), uction of an antigen into a yeast, physical attachment of the
n to the yeast, and mixing of the yeast and antigen together, such as in a buffer or
other solution or ation. These types of complexes are described in detail below.
In one embodiment, a yeast cell used to prepare the yeast vehicle is ected
with a heterologous nucleic acid molecule encoding a protein (e.g., the antigen) such that
the protein is expressed by the yeast cell. Such a yeast is also referred to herein as a
recombinant yeast or a recombinant yeast vehicle. The yeast cell can then be formulated
with a pharmaceutically acceptable excipient and administered directly to a patient, stored
for later administration, or loaded into a dendritic cell as an intact cell. The yeast cell can
also be killed, or it can be derivatized such as by formation of yeast spheroplasts,
cytoplasts, , or subcellular particles, any of which may be followed by storing,
administering, or loading of the derivative into the dendritic cell. Yeast spheroplasts can
also be directly transfected with a recombinant c acid molecule (e.g., the spheroplast
is produced from a whole yeast, and then transfected) in order to produce a recombinant
plast that expresses the antigen. Yeast cells or yeast spheroplasts that
recombinantly express the antigen(s) may be used to produce a yeast vehicle comprising a
yeast cytoplast, a yeast ghost, or a yeast membrane particle or yeast cell wall particle, or
fraction thereof.
In general, the yeast vehicle and antigen(s) and/or other agents can be
associated by any technique described herein. In one aspect, the yeast vehicle was loaded
intracellularly with the antigen(s) and/or agent(s). In another aspect, the antigen(s) and/or
agent(s) was covalently or non-covalently attached to the yeast vehicle. In yet another
aspect, the yeast vehicle and the n(s) and/or agent(s) were ated by mixing. In
another aspect, and in one embodiment, the antigen(s) and/or agent(s) are expressed
inantly by the yeast e or by the yeast cell or yeast spheroplast from which the
yeast vehicle was derived.
A number of antigens and/or other proteins to be produced by a yeast vehicle
of the present invention is any number of antigens and/or other proteins that can be
reasonably produced by a yeast vehicle, and typically ranges from at least one to at least
about 6 or more, including from about 2 to about 6 antigens and or other proteins.
Expression of an antigen or other n in a yeast vehicle of the present
ion is accomplished using techniques known to those skilled in the art. Briefly, a
nucleic acid molecule ng at least one desired antigen or other protein is inserted into
an expression vector in such a manner that the nucleic acid molecule is operatively linked
to a transcription control sequence in order to be capable of effecting either constitutive or
regulated expression of the nucleic acid molecule when transformed into a host yeast cell.
c acid molecules encoding one or more antigens and/or other proteins can be on one
or more expression vectors operatively linked to one or more expression control sequences.
Particularly important expression control ces are those which control transcription
initiation, such as promoter and am activation sequences. Any suitable yeast
promoter can be used in the t invention and a variety of such promoters are known
to those skilled in the art. Promoters for expression in Saccharomyces cerevisiae include,
but are not limited to, promoters of genes encoding the following yeast ns: alcohol
dehydrogenase I (ADHl) or II (ADH2), CUPl, phosphoglycerate kinase (PGK), triose
phosphate isomerase (TPI), translational elongation factor EF-l alpha (TEF2),
glyceraldehydephosphate dehydrogenase (GAPDH; also referred to as TDH3, for triose
phosphate dehydrogenase), galactokinase , galactose-l-phosphate uridyl-
transferase (GAL7), UDP-galactose epimerase (GALlO), cytochrome cl (CYCl), Sec7
protein (SEC7) and acid phosphatase (PHOS), including hybrid promoters such as
APDH and ALI0 promoters, and including the ADH2/GAPDH promoter,
which is d when glucose concentrations in the cell are low (e.g., about 0.1 to about
0.2 percent), as well as the CUPI promoter and the TEF2 er. Likewise, a number
of upstream activation sequences (UASs), also referred to as enhancers, are known.
Upstream activation sequences for expression in romyces cerevisiae include, but
are not limited to, the UASs of genes encoding the ing proteins: PCKl, TPI, TDH3,
CYCl, ADHl, ADH2, SUC2, GALl, GAL7 and GALlO, as well as other UASs activated
by the GAL4 gene product, with the ADH2 UAS being used in one aspect. Since the
ADH2 UAS is activated by the ADRl gene product, it may be preferable to overexpress
the ADRl gene when a heterologous gene is operatively linked to the ADH2 UAS.
Transcription termination sequences for expression in Saccharomyces cerevisiae include
the termination ces of the u-factor, GAPDH, and CYCl genes.
ription control sequences to express genes in methyltrophic yeast
include the transcription control regions of the genes encoding l oxidase and
formate dehydrogenase.
Transfection of a nucleic acid molecule into a yeast cell according to the
present invention can be accomplished by any method by which a nucleic acid molecule
can be introduced into the cell and includes, but is not limited to, diffusion, active
transport, bath sonication, electroporation, microinjection, lipofection, tion, and
protoplast fusion. Transfected nucleic acid molecules can be integrated into a yeast
chromosome or maintained on extrachromosomal vectors using techniques known to those
skilled in the art. Examples of yeast vehicles carrying such nucleic acid molecules are
disclosed in detail herein. As discussed above, yeast cytoplast, yeast ghost, and yeast
ne particles or cell wall ations can also be produced recombinantly by
transfecting intact yeast microorganisms or yeast spheroplasts with d nucleic acid
molecules, producing the antigen therein, and then further manipulating the
microorganisms or spheroplasts using techniques known to those skilled in the art to
produce cytoplast, ghost or subcellular yeast ne extract or fractions thereof
containing desired antigens or other proteins.
Effective conditions for the production of inant yeast vehicles and
expression of the antigen and/or other protein by the yeast vehicle include an effective
medium in which a yeast strain can be cultured. An effective medium is typically an
aqueous medium comprising lable carbohydrate, nitrogen and phosphate sources, as
well as appropriate salts, minerals, metals and other nutrients, such as Vitamins and growth
factors. The medium may comprise complex nutrients or may be a defined minimal
. Yeast strains of the present invention can be cultured in a variety of containers,
including, but not limited to, bioreactors, Erlenmeyer flasks, test tubes, microtiter dishes,
and Petri plates. Culturing is carried out at a temperature, pH and oxygen content
riate for the yeast strain. Such culturing conditions are well within the expertise of
one of ordinary skill in the art (see, for example, Guthrie et al. (eds.), 1991, Methods in
Enzymology, vol. 194, Academic Press, San Diego). For example, under one protocol,
liquid cultures containing a suitable medium can be ated using cultures obtained
from starter plates and/or starter es of Brachyury therapy compositions,
and are grown for approximately 20h at 30°C, with agitation at 250 rpm. Primary cultures
can then be expanded into larger cultures as desired. Protein expression from vectors with
which the yeast were transformed (e.g., Brachyury expression) may be constitutive if the
promoter utilized is a constitutive promoter, or may be induced by addition of the
appropriate induction conditions for the promoter if the promoter utilized is an inducible
promoter (e.g., copper sulfate in the case of the CUP] promoter). In the case of an
inducible promoter, induction of protein expression may be initiated after the e has
grown to a suitable cell y, which may be at about 0.2 Y.U./ml or higher ies.
One miting example of a medium le for the culture of a yeast-
Brachyury immunotherapy composition of the invention is U2 medium. U2 medium
comprises the following components: 20g/L of glucose, 6.7 g/L of Yeast nitrogen base
containing um sulfate, and 0.04 mg/mL each of histidine, leucine, tryptophan, and
adenine. Another non-limiting example of a medium suitable for the culture of yeast-
Brachyury immunotherapy composition of the invention is UL2 medium. UL2 medium
comprises the following components: 20g/L of glucose, 6.7 g/L of Yeast nitrogen base
containing ammonium sulfate, and 0.04 mg/mL each of histidine, tryptophan, and adenine.
] In one embodiment of the invention, when an inducible promoter is used (e.g.
the CUPI promoter) to express a Brachyury protein in a yeast e according to the
invention, induction of protein expression is initiated at a higher cell y as ed
to the cell density that would be suitable for most proteins expressed by yeast using such a
promoter. More specifically, the present inventors have ered that optimal
Brachyury antigen expression driven by the CUP] promoter occurs when the yeast
expressing the Brachyury antigen are allowed to grow to a cell density of between at least
0.5 Y.U/ml and approximately 2.0 Y.U./ml, and in one aspect, to between 0.5 Y.U./ml and
approximately 1.5 Y.U./ml, and in one aspect, to between at least 1.0 Y.U./ml and about
2.0 Y.U./ml, and in another , to at least about 1.0 l, prior to inducing
expression of the Brachyury antigen in the yeast. The present inventors have discovered
that uent to induction of Brachyury expression, the yeast will double only about 1X
to l.5X. Moreover, after induction of Brachyury expression, the inventors have
discovered that growth of the yeast to cell densities higher than about 2.0 Y.U./ml, or for
longer than about 6-8 hours, results in decreased ity of the cultures, while not
substantially improving antigen accumulation in the yeast. Therefore, in one embodiment
of the ion, a yeast-Brachyury immunotherapy composition having antigen
expression under the control of an inducible promoter, such as the CUP] promoter, is
grown to g phase prior to inducing antigen expression. In one aspect, the cells are
grown to between about 1 and 2 Y.U./ml prior to induction of antigen expression. In one
aspect, antigen expression is d (e.g., by the addition of copper sulfate) and continues
for up to 6, 6.5, 7, 7.5, or 8 hours. In one aspect, the induction occurs at a temperature of
about 30°C and agitation rate of 250 rpm.
In some embodiments of the invention, the yeast are grown under neutral pH
conditions. As used herein, the l use of the term “neutral pH” refers to a pH range
between about pH 5.5 and about pH 8, and in one , between about pH 6 and about 8.
One of skill the art will appreciate that minor fluctuations (e.g., tenths or dths) can
occur when measuring with a pH meter. As such, the use of neutral pH to grow yeast cells
means that the yeast cells are grown in neutral pH for the majority of the time that they are
in culture. In one embodiment, yeast are grown in a medium maintained at a pH level of
at least 5.5 (i.e., the pH of the culture medium is not allowed to drop below pH 5.5). In
another aspect, yeast are grown at a pH level maintained at about 6, 6.5, 7, 7.5 or 8. The
use of a neutral pH in culturing yeast promotes several biological effects that are desirable
characteristics for using the yeast as vehicles for immunomodulation. For example,,
culturing the yeast in l pH allows for good growth of the yeast without negative
effect on the cell generation time (e.g., g of doubling time). The yeast can continue
to grow to high densities without losing their cell wall pliability. The use of a neutral pH
allows for the production of yeast with pliable cell walls and/or yeast that are more
sensitive to cell wall digesting enzymes (e.g., glucanase) at all harvest densities. This trait
is desirable because yeast with flexible cell walls can induce ent or improved
immune responses as compared to yeast grown under more acidic conditions, e. g., by
promoting the ion of cytokines by antigen presenting cells that have phagocytosed
the yeast (e.g., THl-type cytokines including, but not limited to, IFN-y, interleukin-12 (IL-
12), and IL-2, as well as proinflammatory cytokines such as IL-6). In addition, greater
accessibility to the ns located in the cell wall is afforded by such culture methods. In
another aspect, the use of neutral pH for some antigens allows for release of the di-sulfide
bonded n by treatment with dithiothreitol (DTT) that is not possible when such an
antigen-expressing yeast is cultured in media at lower pH (e.g., pH 5).
In one embodiment, control of the amount of yeast glycosylation is used to
control the expression of antigens by the yeast, particularly on the surface. The amount of
yeast ylation can affect the immunogenicity and antigenicity of the antigen,
particularly one expressed on the surface, since sugar moieties tend to be bulky. As such,
the existence of sugar moieties on the surface of yeast and its impact on the three-
dimensional space around the target antigen(s) should be considered in the modulation of
yeast according to the invention. Any method can be used to reduce the amount of
glycosylation of the yeast (or increase it, if desired). For example, one could use a yeast
mutant strain that has been selected to have low glycosylation (e. g. mnnl, ochl and mnn9
mutants), or one could eliminate by mutation the glycosylation acceptor sequences on the
target n. Alternatively, one could use yeast with abbreviated glycosylation patterns,
e.g., Pichia. One can also treat the yeast using s that reduce or alter the
glycosylation.
In one embodiment of the present ion, as an alternative to expression of
an antigen or other protein recombinantly in the yeast vehicle, a yeast vehicle is loaded
intracellularly with the protein or peptide, or with carbohydrates or other les that
serve as an antigen and/or are useful as immunomodulatory agents or biological response
modifiers according to the invention. Subsequently, the yeast vehicle, which now contains
the n and/or other proteins intracellularly, can be stered to an individual or
loaded into a carrier such as a dendritic cell. Peptides and proteins can be inserted directly
into yeast vehicles of the present invention by techniques known to those skilled in the art,
such as by diffusion, active transport, me fusion, electroporation, ytosis,
freeze-thaw cycles and bath sonication. Yeast vehicles that can be directly loaded with
peptides, proteins, carbohydrates, or other les include intact yeast, as well as
spheroplasts, ghosts or cytoplasts, which can be loaded with antigens and other agents
after production. Alternatively, intact yeast can be loaded with the n and/or agent,
and then spheroplasts, ghosts, cytoplasts, or subcellular particles can be prepared
therefrom. Any number of antigens and/or other agents can be loaded into a yeast vehicle
in this embodiment, from at least 1, 2, 3, 4 or any whole integer up to hundreds or
thousands of antigens and/or other agents, such as would be provided by the loading of a
microorganism or portions f, for example.
In another embodiment of the present invention, an antigen and/or other agent
is physically attached to the yeast vehicle. al attachment of the antigen and/or other
agent to the yeast vehicle can be accomplished by any method suitable in the art, including
covalent and non-covalent association methods which include, but are not limited to,
chemically crosslinking the n and/or other agent to the outer surface of the yeast
vehicle or biologically linking the antigen and/or other agent to the outer e of the
yeast vehicle, such as by using an antibody or other binding partner. Chemical cross-
linking can be achieved, for example, by methods including glutaraldehyde linkage,
photoaffinity labeling, treatment with carbodiimides, treatment with chemicals capable of
linking di-sulf1de bonds, and treatment with other cross-linking chemicals standard in the
art. Alternatively, a chemical can be ted with the yeast vehicle that alters the charge
of the lipid bilayer of yeast membrane or the composition of the cell wall so that the outer
surface of the yeast is more likely to fuse or bind to antigens and/or other agent haVing
ular charge characteristics. Targeting agents such as antibodies, binding peptides,
soluble receptors, and other ligands may also be incorporated into an antigen as a fusion
protein or ise associated with an antigen for binding of the antigen to the yeast
vehicle.
] When the antigen or other protein is expressed on or physically attached to the
surface of the yeast, spacer arms may, in one aspect, be carefully selected to optimize
antigen or other protein expression or content on the surface. The size of the spacer arm(s)
can affect how much of the antigen or other protein is d for binding on the surface
of the yeast. Thus, ing on which antigen(s) or other n(s) are being used, one
of skill in the art will select a spacer arm that effectuates appropriate spacing for the
antigen or other protein on the yeast surface. In one embodiment, the spacer arm is a yeast
protein of at least 450 amino acids. Spacer arms have been sed in detail above.
In yet another embodiment, the yeast e and the antigen or other protein
are associated with each other by a more passive, non-specific or non-covalent binding
mechanism, such as by gently mixing the yeast vehicle and the n or other protein
together in a buffer or other le formulation (e.g., admixture).
In one embodiment, intact yeast (with or without expression of heterologous
antigens or other proteins) can be ground up or processed in a manner to produce yeast
cell wall preparations, yeast membrane particles or yeast fragments (i.e., not ) and
the yeast fragments can, in some embodiments, be provided with or administered with
other compositions that include antigens (e.g., DNA vaccines, protein subunit vaccines,
killed or inactivated pathogens, viral vector vaccines) to enhance immune ses. For
example, enzymatic treatment, chemical treatment or al force (e.g., mechanical
shearing or sonication) can be used to break up the yeast into parts that are used as an
adjuvant.
In one embodiment of the invention, yeast vehicles useful in the invention
include yeast vehicles that have been killed or inactivated. Killing or inactivating of yeast
can be accomplished by any of a variety of suitable methods known in the art. For
example, heat inactivation of yeast is a standard way of inactivating yeast, and one of skill
in the art can monitor the ural s of the target antigen, if desired, by standard
methods known in the art. Alternatively, other methods of inactivating the yeast can be
used, such as chemical, electrical, ctive or UV methods. See, for e, the
methodology disclosed in standard yeast culturing textbooks such as Methods of
Enzymology, Vol. 194, Cold Spring Harbor Publishing (1990). Any of the inactivation
strategies used should take the secondary, tertiary or quaternary structure of the target
antigen into consideration and preserve such structure as to optimize its immunogenicity.
Yeast vehicles can be formulated into based therapy
compositions or products of the present invention using a number of techniques known to
those skilled in the art. For example, yeast vehicles can be dried by lyophilization.
Formulations comprising yeast vehicles can also be prepared by packing yeast in a cake or
a tablet, such as is done for yeast used in baking or brewing operations. In addition, yeast
vehicles can be mixed with a pharmaceutically acceptable excipient, such as an isotonic
buffer that is ted by a host or host cell. Examples of such excipients include water,
saline, Ringer's solution, se solution, Hank's solution, and other aqueous
physiologically balanced salt solutions. Nonaqueous vehicles, such as fixed oils, sesame
oil, ethyl oleate, or triglycerides may also be used. Other useful formulations include
sions containing viscosity-enhancing agents, such as sodium
carboxymethylcellulose, sorbitol, ol or dextran. Excipients can also contain minor
amounts of additives, such as nces that enhance isotonicity and chemical ity.
Examples of buffers include phosphate buffer, bicarbonate buffer and Tris buffer, while
examples of preservatives include thimerosal, m- or o-cresol, formalin and benzyl l.
Standard formulations can either be liquid injectables or solids which can be taken up in a
suitable liquid as a sion or solution for injection. Thus, in a non-liquid formulation,
the excipient can comprise, for example, dextrose, human serum albumin, and/or
preservatives to which sterile water or saline can be added prior to stration.
] In one embodiment of the present invention, a composition can include
additional , which may also be referred to as biological response r
compounds, or the ability to produce such agents/modifiers. For example, a yeast vehicle
can be transfected with or loaded with at least one antigen and at least one agent/biological
response modifier compound, or a composition of the invention can be administered in
conjunction with at least one agent/biological response modifier. Biological response
modifiers e adjuvants and other compounds that can modulate immune responses,
which may be referred to as immunomodulatory compounds, as well as compounds that
modify the biological activity of another nd or agent, such as a yeast-based
immunotherapeutic, such biological activity not being limited to immune system s.
Certain immunomodulatory nds can stimulate a protective immune response
whereas others can suppress a harmful immune response, and whether an
immunomodulatory is useful in combination with a given yeast-based immunotherapeutic
may depend, at least in part, on the disease state or condition to be treated or prevented,
and/or on the individual who is to be treated. Certain biological response modifiers
preferentially e a cell-mediated immune response whereas others preferentially
enhance a humoral immune response (i.e., can stimulate an immune response in which
there is an increased level of cell-mediated compared to humoral immunity, or vice versa.).
n biological response rs have one or more properties in common with the
biological properties of yeast-based immunotherapeutics or enhance or complement the
biological properties of yeast-based immunotherapeutics. There are a number of
techniques known to those skilled in the art to measure stimulation or suppression of
immune responses, as well as to differentiate cell-mediated immune responses from
humoral immune responses, and to differentiate one type of cell-mediated response from
another (e. g., a THl7 se versus a THl response).
Agents/biological response modifiers useful in the invention may include, but
are not limited to, cytokines, chemokines, hormones, lipidic derivatives, peptides, proteins,
polysaccharides, small molecule drugs, antibodies and antigen binding fragments thereof
(including, but not limited to, anti-cytokine antibodies, ytokine receptor antibodies,
anti-chemokine dies), ns, polynucleotides, nucleic acid binding moieties,
aptamers, and growth modulators. Some suitable agents include, but are not limited to,
IL-1 or agonists of IL-1 or of IL-lR, anti-IL-l or other IL-l antagonists; IL-6 or agonists
of IL-6 or of IL-6R, anti-IL-6 or other IL-6 antagonists; IL-12 or agonists of IL-12 or of
IL-l2R, anti-IL-12 or other IL-12 antagonists; IL-17 or agonists of IL-17 or of IL-l7R,
anti-IL-l7 or other IL-l7 antagonists; IL-21 or agonists of IL-21 or of IL-21R, anti-IL-21
or other IL-21 antagonists; IL-22 or agonists of IL-22 or of IL-22R, L-22 or other IL-
22 nists; IL-23 or agonists of IL-23 or of IL-23R, anti-IL-23 or other IL-23
antagonists; IL-25 or agonists of IL-25 or of IL-25R, anti-IL-25 or other IL-25
antagonists; IL-27 or ts of IL-27 or of IL-27R, anti-IL-27 or other IL-27
antagonists; type I interferon (including IFN—u) or agonists or antagonists of type I
eron or a receptor thereof; type II interferon (including IFN—y) or agonists or
antagonists of type II interferon or a receptor thereof; anti-CD40, CD40L, lymphocyte-
activation gene 3 (LAG3) protein and/or IMP321 (T-cell immunostimulatory factor
derived from the soluble form of LAG3), anti-CTLA-4 dy (e.g., to release anergic T
cells); T cell co-stimulators (e.g., anti-CD137, anti-CD28, anti-CD40); alemtuzumab (e.g.,
CamPath®), denileukin diftitox (e.g., ONTAK®); anti-CD4; anti-CD25; anti-PD-l, anti-
PD-Ll, anti-PD-L2; agents that block FOXP3 (e.g., to abrogate the ty/kill
CD4+/CD25+ T tory cells); Flt3 ligand, mod (AldaraTM), granulocyte-
macrophage colony stimulating factor (GM-CSF); granulocyte-colony stimulating factor
), sargramostim (Leukine®); hormones including Without limitation prolactin and
growth hormone; Toll-like receptor (TLR) agonists, including but not limited to TLR-2
agonists, TLR-4 agonists, TLR-7 agonists, and TLR-9 agonists; TLR antagonists,
including but not limited to TLR-2 antagonists, TLR-4 antagonists, TLR-7 antagonists,
and TLR-9 nists; anti-inflammatory agents and modulators, including but
not d to, COX-2 inhibitors (e.g., Celecoxib, NSAIDS), glucocorticoids, statins, and
thalidomide and analogues thereof ing IMiDTMs (Which are ural and functional
analogues of thalidomide (e.g., REVLIMID® (lenalidomide), ACTIMID®
(pomalidomide)); proinflammatory agents, such as fungal or bacterial components or any
proinflammatory cytokine or chemokine; immunotherapeutic vaccines including, but not
limited to, Virus-based vaccines, bacteria-based vaccines, or antibody-based vaccines; and
any other immunomodulators, immunopotentiators, anti-inflammatory agents, pro-
inflammatory agents, and any agents that modulate the number of, modulate the activation
state of, and/or modulate the survival of antigen-presenting cells or of THl7, THl, and/or
Treg cells. Any combination of such agents is contemplated by the invention, and any of
such agents combined with or administered in a protocol with (e.g., rently,
sequentially, or in other formats with) a yeast-based immunotherapeutic is a composition
assed by the invention. Such agents are well known in the art. These agents may
be used alone or in combination with other agents described herein.
Agents can include agonists and antagonists of a given protein or peptide or
domain thereof. As used herein, an “agonist” is any compound or agent, ing without
limitation small molecules, proteins, peptides, antibodies, nucleic acid binding agents, etc.,
that binds to a or or ligand and produces or triggers a response, which may include
agents that mimic or enhance the action of a naturally occurring substance that binds to the
receptor or ligand. An “antagonist” is any compound or agent, including without
limitation small molecules, proteins, peptides, antibodies, nucleic acid g agents, etc.,
that blocks or inhibits or reduces the action of an agonist.
Compositions of the invention can further include or can be administered with
(concurrently, sequentially, or intermittently with) any other agents or compositions or
protocols that are useful for preventing or ng cancer or any compounds that treat or
ameliorate any m of cancer, and particularly s associated with Brachyury
expression or overexpression. In addition, compositions of the invention can be used
together with other immunotherapeutic compositions, including prophylactic and/or
therapeutic immunotherapy. Indeed, the compositions of the invention can be used to
inhibit or reduce chemotherapy resistance or radiation resistance that may occur in
metastatic cancer by inhibiting Brachyury sion in the cancer (and thereby inhibiting
anti-proliferative influences) or compositions of the invention may enhance the
performance of herapy or radiation therapy in an individual. Additional agents,
compositions or protocols (e.g., therapeutic ols) that are useful for the treatment of
cancer e, but are not limited to, chemotherapy, al resection of a tumor,
radiation therapy, allogeneic or autologous stem cell transplantation, and/or targeted
cancer therapies (e.g., small molecule drugs, biologics, or monoclonal antibody ies
that specifically target les involved in tumor growth and progression, including, but
not limited to, selective estrogen receptor tors (SERMs), aromatase inhibitors,
tyrosine kinase tors, serine/threonine kinase inhibitors, histone deacetylase (HDAC)
inhibitors, retinoid receptor activators, apoptosis stimulators, angiogenesis inhibitors, poly
(ADP-ribose_) polymerase (PARP) inhibitors, or immunostimulators). Any of these
additional therapeutic agents and/or therapeutic protocols may be administered before,
concurrently with, ating with, or after the immunotherapy compositions of the
invention, or at different time points. For example, when given to an individual in
conjunction with chemotherapy or a targeted cancer therapy, it may be desirable to
administer the yeast-Brachyury immunotherapy compositions during the “holiday”
between doses of chemotherapy or targeted cancer therapy, in order to maximize the
efficacy of the immunotherapy compositions. Surgical resection of a tumor may
frequently e administration of a yeast-Brachyury immunotherapy composition, but
additional or primary surgery may occur during or after administration of a yeast-
Brachyury therapy composition.
The invention also es a kit comprising any of the compositions
described herein, or any of the individual components of the compositions described
herein. Kits may include additional reagents and written instructions or ions for
using any of the compositions of the invention to prevent or treat cancer associated with
Brachyury expression or overexpression.
Methods for Administration or Use of Coonsitions o: the ion
Yeast-Brachyury immunotherapeutic compositions of the invention are
designed for use to prevent or treat cancers that are associated with or characterized by
Brachyury expression or overexpression, including by preventing emergence of such
cancers, arresting ssion of such cancers or eliminating such cancers. More
particularly, yeast-Brachyury immunotherapeutic compositions can be used to prevent,
inhibit or delay the development of ury-expressing tumors, and/or to prevent,
inhibit or delay tumor migration and/or tumor invasion of other tissues (metastases) and/or
to lly prevent or inhibit progression of cancer in an individual. Yeast-Brachyury
immunotherapeutic compositions can also be used to ameliorate at least one symptom of
the cancer, such as by reducing tumor burden in the dual; inhibiting tumor growth in
the individual; increasing survival of the individual; preventing, inhibiting, reversing or
delaying development of tumor migration and/or tumor invasion of other tissues
(metastatic cancer) and/or ting, inhibiting, reversing or delaying progression of the
cancer in the dual. Brachyury immunotherapy can also be used
therapeutically to inhibit, reduce or eliminate chemotherapy resistance or ion
resistance that may occur in metastatic cancer by inhibiting Brachyury expression in the
cancer, and compositions of the invention may enhance the performance of herapy
or radiation therapy in an individual.
Cancers that are relevant to the compositions and methods of the invention are
any cancer that expresses, or may s, Brachyury, or cancers in proximity to cancers
that s or may express Brachyury, and include, but are not limited to, cancer of the
breast, small intestine, stomach, kidney, bladder, , ovary, testes, lung, colon,
pancreas, or prostate, and include metastatic and late-stage cancers. In addition,
Brachyury is expressed in tumors of B cell origin, such as chronic lymphocytic leukemia
(CLL), Epstein-Barr virus transformed B cells, Burkitt’s and n’s lymphomas, as
well as metastatic cancers thereof.
One embodiment of the ion relates to a method to inhibit tumor
ion and/or to reduce, halt (arrest), reverse or prevent the metastatic progression of
cancer in an individual who has cancer, or to reverse the development of metastatic events
in a cancer. As discussed above, ury promotes the epithelial-mesenchymal
transition (EMT) in human tumor cells, conferring on tumor cells a mesenchymal
phenotype, as well as migratory and invasive abilities, while attenuating tumor cell cycle
ssion. Therefore, the involvement of Brachyury in atic processes makes it an
ideal target for the prevention or inhibition of metastatic processes, including arresting
cancer at a pre-metastatic stage. Use of a yeast-Brachyury immunotherapeutic
composition of the invention can be effective to prevent or treat metastatic ,
including arresting progression of the cancer, in the face of escape (or attempted escape)
of the cancer from traditional therapy, such as chemotherapy and radiation. The method
es the steps of administering to the individual who has cancer an immunotherapeutic
composition a Brachyury immunotherapeutic composition of the invention as
described , ing, but not limited to: (a) a yeast vehicle; and (b) a cancer
n comprising at least one Brachyury antigen.
In one aspect, Brachyury is not detected in the individual’s cancer at the time
the composition is first administered. In general, when Brachyury is not detected in the
individual’s cancer, the individual may have an earlier stage cancer in which Brachyury
expression has not yet manifested (e.g., stage I or stage II), or in which Brachyury
expression is not yet detectable in any event (i.e., Brachyury may or may not be expressed
at a low level or in a small number of tumor cells, but is not yet readily detectable using
standard detection methods). In this aspect of the invention, the development of
Brachyury-expressing tumor cells is prevented, delayed or inhibited by use of the yeast-
Brachyury immunotherapeutic composition. As a result, tumor migration and/or other
metastatic ses leading to metastatic progression of the tumor are prevented, delayed
or inhibited and/or general arrest of tumor progression occurs in the individual.
In r aspect, Brachyury expression is or can be detected in the
individual’s cancer at the time the composition is first administered. The individual may
have stage I, stage II, stage III, or stage IV cancer in this aspect of the invention. In this
aspect, use of the Brachyury immunotherapeutic composition s, eliminates or
slows or arrests the growth of tumors expressing Brachyury, which can result in reduction
in tumor burden in the individual, inhibition of Brachyury-expressing tumor growth,
and/or increased survival of the individual. The individual may experience an arrest,
g or reversal in atic processes, improving survival and health of the patient,
and furthermore, allowing other therapeutic protocols to treat the cancer.
Indeed, metastatic cancer can be associated with resistance, or increased
resistance, to cancer therapies such as chemotherapy, radiation, or targeted cancer y,
whereby the cancer “escapes” from the therapy or is simply less impacted by the therapy
and progresses. ingly, there is a need to reduce or eliminate resistance to such
therapies to improve or enhance the efficacy of the therapy and improve patient health and
survival. Accordingly, one ment of the invention relates to a method to reduce or
prevent chemotherapy-resistance, targeted cancer therapy-resistance, or radiation-
resistance in a patient with cancer. The method comprises administering to an individual
who has cancer and is receiving chemotherapy and/or radiation therapy for the cancer, a
yeast-Brachyury immunotherapeutic composition as described herein, which may include
a composition comprising: (a) a yeast vehicle; and (b) a cancer antigen comprising at least
one Brachyury antigen. This method of the invention may also be used to treat resistance
associated with other therapeutic treatments for , including, but not limited to,
targeted cancer y.
] In one aspect of this embodiment, Brachyury is not detected in the individual’s
cancer at the time the composition is first administered. In this aspect, administration of a
yeast-Brachyury immunotherapeutic composition prevents or ts the onset of
resistance to chemotherapy or radiation therapy by inhibiting the pment of
Brachyury-expressing tumor cells in the cancer. In another aspect, Brachyury expression
is detected in the dual’s cancer at the time the composition is first administered. In
this aspect, the individual may or may not already be experiencing resistance to
chemotherapy or radiation. In either case, administration of the yeast-Brachyury
immunotherapeutic composition of the invention prevents or inhibits the resistance to
chemotherapy or ion therapy or enhances the ability of the chemotherapy or
radiation therapy to treat the individual, by reducing or eliminating Brachyury-expressing
tumor cells in the patient.
Another embodiment of the invention relates to a method to treat cancer, and
particularly, a Brachyury-expressing cancer. The method includes administering to an
dual who has a ury-expressing cancer a yeast-Brachyury therapeutic
composition described herein, which can include a composition comprising: (a) a yeast
vehicle; and (b) a cancer antigen comprising at least one Brachyury antigen. In one aspect,
the method reduces tumor burden in the patient. In one aspect, the method increases
survival of the patient. In one aspect, the method inhibits tumor growth in the indiVidual.
In one aspect, the method ts, arrests or reverses metastatic progression of the tumor.
Since Brachyury expression is believed to be more prevalent as a cancer
advances or progresses into higher stages (e.g., from stage I to stage II to stage III to stage
IV, depending on the particular cancer) and is associated with metastatic processes, it is an
embodiment of the invention to provide a method to prevent or delay the onset of a
Brachyury-expressing cancer, or to arrest the cancer at a pre-metastatic or pre-malignant
stage. Such a method includes administering to an dual in whom Brachyury-
expressing cancer cells are not detected a yeast-Brachyury immunotherapeutic
composition described herein, which can include a ition comprising: (a) a yeast
vehicle; and (b) a cancer antigen comprising at least one Brachyury antigen. In one aspect
of this embodiment, the cancer is known to express or believed to be susceptible to
expressing Brachyury at some stage of the cancer in at least a subset of indiViduals with
the cancer. In one aspect of this embodiment, the dual already has a cancer, but
Brachyury is not ed in the cancer at the time the composition is first administered,
meaning that the indiVidual may have an earlier stage cancer in which Brachyury
expression has not yet sted, or in which ury expression is not yet detectable
in any event (i.e., Brachyury may or may not be sed at a low level or in a small
number of tumor cells, but is not yet y detectable using standard detection methods).
In some cases, the type of cancer may be known to have a high rate of metastatic
progression, In this aspect, administration of the yeast-Brachyury immunotherapeutic
composition prevents, delays or inhibits the development of Brachyury-expressing tumor
cells in the patient’s cancer, and therefore prevents, arrests, delays or inhibits metastatic
processes that any Brachyury expression. In another aspect, the indiVidual does
not have cancer when the composition is administered. Such an individual may be
“predisposed” or likely to p cancer, perhaps because of family history or a genetic
, or because the dual has shown signs of precancerous cells or lesions or has
precancerous (premalignant) cells or lesions.
In one aspect, the individual is additionally treated with at least one other
therapeutic compound or therapeutic protocol useful for the treatment of cancer. Such
therapeutic agents and ols have been discussed in detail elsewhere herein. For
example, in any of the embodiments regarding methods of the invention described ,
in one aspect, when the individual has cancer (regardless of the status of detectable
Brachyury expression in tumor cells) the individual is being treated or has been treated
with another therapy for cancer. Such therapy can e any of the therapeutic protocols
or use of any therapeutic compound or agent described previously herein, including, but
not limited to, chemotherapy, ion therapy, targeted cancer therapy, surgical resection
of a tumor, stem cell transfer, cytokine therapy, adoptive T cell transfer, and/or
administration of a second immunotherapeutic composition. In the case of administration
of a second immunotherapeutic composition, such compositions may include, but are not
limited to, additional yeast-based immunotherapy, recombinant virus-based
immunotherapy (viral vectors), cytokine therapy, immunostimulant therapy (including
chemotherapy with immunostimulating properties), DNA vaccines, and other
immunotherapy compositions.
In one , the second therapeutic composition includes a second
cancer n that does not include Brachyury antigen. For example, a second
immunotherapeutic composition useful in combination with a yeast-Brachyury
immunotherapeutic composition is a yeast-immunotherapeutic composition comprising
another cancer antigen. Such cancer antigens may include, but are not limited to,
carcinoembryonic antigen (CEA), point mutated Ras oncoprotein, MUC-l, EGFR, BCR-
Abl, MART-l, MAGE-l, MAGE-3, GAGE, , MUC-2, normal and point d
p53 oncoproteins, PSMA, tyrosinase, TRP-l , NY-ESO-l, TRP-2, TAG72, KSA,
CA-125, PSA, neu/c-erb/B2, hTERT, p73, B-RAF, adenomatous sis coli
(APC), Myc, von Hippel-Lindau protein (VHL), Rb-l, Rb-2, androgen receptor (AR),
Smad4, MDRl, Flt-3, BRCA-l, BRCA-2, pax3-fl<hr, ews-fli-l, HERV-H, HERV-K,
TWIST, Mesothelin, NGEP, modifications of such antigens, splice variants of such
ns, and epitope agonists of such antigens, as well as combinations of such antigens,
and/or immunogenic domains thereof, ations thereof, variants thereof, and/or
epitope agonists thereof
] As used , to “treat” a cancer, or any ation thereof (e.g., “treated
for cancer”, etc.) generally refers to administering a composition of the invention once the
cancer has occurred (e.g., once the cancer has been diagnosed or detected in an dual),
with at least one therapeutic goal of the treatment (as compared to in the absence of this
treatment) including: ion in tumor burden, inhibition of tumor growth, se in
survival of the individual, delaying, inhibiting, arresting or preventing the onset or
development of metastatic cancer (such as by delaying, inhibiting, ing or preventing
the onset of development of tumor migration and/or tumor invasion of tissues outside of
y cancer and/or other processes associated with metastatic progression of cancer),
delaying or arresting cancer progression, improvement of immune responses against the
tumor, improvement of long term memory immune responses against the tumor antigens,
and/or improved general health of the individual. To “prevent” or “protect” from a cancer,
or any permutation thereof (e.g., “prevention of cancer”, etc.), generally refers to
administering a composition of the invention before a cancer has occurred, or before a
specific stage of cancer or tumor antigen expression in a cancer has occurred (e.g., before
Brachyury expression is ed in the cancer), with at least one goal of the treatment (as
compared to in the absence of this treatment) including: preventing or delaying the onset
or development of a cancer, or, should the cancer occur after the treatment, at least
reducing the severity of the cancer (e. g., reducing the level of tumor growth, arresting
cancer progression, improving the immune response against the cancer, inhibiting
metastatic processes) or improving outcomes in the individual (e.g., improving survival).
The present invention includes the delivery (administration, immunization) of
a yeast-Brachyury immunotherapeutic composition of the invention to a subject or
individual. The administration process can be performed ex vivo or in viva, but is lly
performed in viva. Ex vivo administration refers to performing part of the regulatory step
outside of the t, such as administering a ition of the present invention to a
population of cells (dendritic cells) removed from a patient under conditions such that a
yeast vehicle, antigen(s) and any other agents or itions are loaded into the cell, and
returning the cells to the patient. The therapeutic composition of the present invention can
be returned to a t, or administered to a patient, by any le mode of
administration.
stration of a composition can be systemic, l and/or proximal to
the location of the target site (e. g., near a site of a tumor). le routes of
administration will be apparent to those of skill in the art, depending on the type of cancer
to be prevented or treated and/or the target cell population or tissue. Various acceptable
s of administration include, but are not limited to, intravenous administration,
intraperitoneal administration, intramuscular administration, intranodal administration,
oronary administration, intraarterial administration (e.g., into a carotid artery),
subcutaneous administration, transdermal delivery, intratracheal administration,
rticular administration, intraventricular administration, inhalation (e.g., aerosol),
ranial, intraspinal, cular, aural, asal, oral, pulmonary administration,
impregnation of a catheter, and direct injection into a tissue. In one aspect, routes of
administration include: intravenous, intraperitoneal, subcutaneous, intradermal, intranodal,
intramuscular, transdermal, inhaled, asal, oral, intraocular, intraarticular, intracranial,
and intraspinal. Parenteral delivery can include intradermal, intramuscular, intraperitoneal,
leural, intrapulmonary, intravenous, subcutaneous, atrial catheter and venal er
routes. Aural delivery can e ear drops, intranasal delivery can include nose drops or
intranasal injection, and intraocular delivery can include eye drops. Aerosol (inhalation)
delivery can also be performed using methods standard in the art (see, for example,
Stribling et al., Proc. Natl. Acad. Sci. USA 189:11277-11281, 1992). In one aspect, a
yeast-Brachyury immunotherapeutic composition of the invention is administered
subcutaneously. In one aspect, the yeast-Brachyury immunotherapeutic composition is
administered directly into a tumor milieu.
In general, a suitable single dose of a Brachyury immunotherapeutic
composition is a dose that is e of effectively ing a yeast vehicle and the
Brachyury antigen to a given cell type, tissue, or region of the patient body in an amount
effective to elicit an antigen-specific immune response against one or more Brachyury
antigens or epitopes, when administered one or more times over a suitable time period.
For example, in one embodiment, a single dose of a yeast-Brachyury of the present
invention is from about 1 x 105 to about 5 x 107 yeast cell equivalents per kilogram body
weight of the organism being administered the composition. In one aspect, a single dose
of a yeast vehicle of the present invention is from about 0.1 Yeast Units (Y.U., which is 1
x 106 yeast cells or yeast cell equivalents) to about 100 Y.U. (1 x 109 cells) per dose (i.e.,
per organism), including any interim dose, in increments of 0.1 x 106 cells (i.e., 1.1 x 106,
1.2 x 106, 1.3 x 106...). In one embodiment, a suitable dose includes doses between 1 Y.U.
and 40 Y.U. and in one aspect, between 10 Y.U. and 40 Y.U. In one embodiment, the
doses are administered at different sites on the individual but during the same dosing
period. For example, a 40 Y.U. dose may be administered by ing 10 Y.U. doses to
four different sites on the individual during one dosing period. The invention includes
administration of an amount of the Brachyury immunotherapy composition (e.g., 1,
2, 3, 4, 5, 6, 7, 8, 9 10, 11, 12, 13, 14,15, 16, 17, 18, 19, 20 Y.U. or more) at 1, 2, 3, 4, 5, 6,
7, 8, 9, 10, or more different sites on an individual to form a single dose. One Yeast Unit
(Y.U.) is 1 x 107 yeast cells or yeast cell equivalents.
"Boosters" or "boosts" of a eutic composition are administered, for
example, when the immune response against the antigen has waned or as needed to
provide an immune response or induce a memory response against a particular antigen or
n(s). Boosters can be stered about 1, 2, 3, 4, 5, 6, 7, or 8 weeks apart, or
monthly, hly, quarterly, annually, and/or in a few or several year increments after
the original administration, depending on the status of the individual being treated and the
goal of the therapy at the time of administration (e.g., lactic, active treatment,
maintenance). In one embodiment, an administration schedule is one in which doses of
yeast-Brachyury therapeutic composition is stered at least 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, or more times over a time period of from weeks, to months, to years. In one
embodiment, the doses are administered weekly or biweekly for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
or more doses, followed by biweekly or monthly doses as needed to achieve the d
preventative or therapeutic treatment for cancer. Additional boosters can then be given at
similar or longer als (months or years) as a maintenance or remission therapy, if
desired.
In one aspect of the invention, one or more additional therapeutic agents or
eutic protocols are stered or performed sequentially and/or concurrently with
the administration of the yeast-Brachyury immunotherapy composition (e.g., surgical
resection of the tumor, administration of chemotherapy, administration of radiation
therapy, administration of another immunotherapy composition or protocol, cytokine
therapy, adoptive T cell transfer, or stem cell transplantation). For example, one or more
therapies can be administered or performed prior to the first dose of yeast-Brachyury
therapy composition or after the first dose is administered. In one embodiment,
one or more therapies can be administered or performed in an alternating manner with the
dosing of yeast-Brachyury immunotherapy composition, such as in a protocol in which the
yeast-Brachyury composition is administered at prescribed intervals in between one or
more consecutive doses of chemotherapy or other therapy. In one embodiment, the yeast-
Brachyury immunotherapy composition is administered in one or more doses over a
period of time prior to commencing additional therapies. In other words, the yeast-
Brachyury immunotherapeutic composition is administered as a erapy for a period
of time, and then an additional therapy is added (e.g., herapy), either concurrently
with new doses of yeast-Brachyury immunotherapy, or in an alternating fashion with
yeast-Brachyury immunotherapy. Alternatively or in addition, another therapy may be
administered for a period of time prior to ing administration of the yeast-Brachyury
immunotherapy composition, and the concepts may be combined (e.g., surgical resection
of a tumor, followed by monotherapy with yeast-Brachyury immunotherapy for several
weeks, followed by alternating doses of chemotherapy and yeast-Brachyury
immunotherapy for weeks or months, optionally followed by monotherapy using yeast-
Brachyury immunotherapy or another y, or by a new ol of ations of
therapy provided sequentially, concurrently, or in alternating fashion). Various protocols
for the treatment of cancer using yeast-Brachyury therapy are contemplated by the
invention, and these examples should be considered to be non-limiting examples of
various possible protocols.
In one aspect of the invention, additional antigens other than Brachyury are
also targeted using yeast-based immunotherapy, in on to targeting Brachyury. Such
additional target antigens can be included within the same yeast-vehicle as the ury
ns, or additional yeast-based immunotherapy compositions targeting different
antigens can be produced and then combined as desired ing on the individual to be
treated, the antigens expressed by the type of cancer or by the individual’s particular tumor,
and/or depending on the stage of cancer in the individual, or the stage of treatment of the
individual. For es a combination of antigens may be selected that cover: (1)
antigens involved in seminal events in cancer development, such as mutated Ras, antigens
involved in or associated with dysregulation of cellular processes, such as CEA, and (3)
Brachyury, which is ed in metastatic processes. For example, on or more other
based immunotherapy compositions may express one or more antigens including,
but not limited to, carcinoembryonic antigen (CEA), point mutated Ras oncoprotein,
MUC-l, EGFR, BCR—Abl, MART-l, MAGE-l, MAGE-3, GAGE, GP-lOO, MUC-2,
normal and point mutated p53 oncoproteins, PSMA, tyrosinase, TRP-l (gp75), NY-ESO-l,
TRP-2, TAG72, KSA, CA-125, PSA, HER-2/neu/c-erb/B2, hTERT, p73, B-RAF,
adenomatous polyposis coli (APC), Myc, von -Lindau protein (VHL), Rb-l, Rb-2,
androgen receptor (AR), Smad4, MDRl, Flt-3, BRCA-l, BRCA-2, an3-fl<hr, ews-fii-l,
HERV-H, HERV-K, TWIST, Mesothelin, NGEP, modifications of such antigens, splice
variants of such antigens, and epitope agonists of such antigens, as well as combinations
of such antigens, and/or immunogenic domains thereof, modifications thereof, variants
thereof, and/or epitope agonists thereof. One, two, three, or more of these yeast-based
immunotherapy itions may be administered to an individual prior to, concurrently
or alternating with, and/or after administration of a yeast-Brachyury immunotherapy
composition, in order to optimize targeting of antigens in the individual’s tumor. As
above, additional therapies can also be used in such protocols (e.g., surgical resection of
tumor, chemotherapy, targeted cancer therapy, radiation therapy, etc.).
In one embodiment of the ion, a method to treat cancer is provided. The
method includes the steps of: (a) administering to an individual who has cancer in which
ury expression has not been detected, a first immunotherapeutic ition
comprising a yeast vehicle and a first cancer antigen that does not comprise a Brachyury
antigen; and (b) administering to the individual, prior to, concurrently with, or subsequent
to, administration of the first immunotherapeutic composition a second
immunotherapeutic ition sing a yeast vehicle and a second cancer antigen
comprising a ury antigen. In additional embodiments, the method can include
administering one or more additional immunotherapeutic compositions, wherein the each
of the one or more additional immunotherapeutic compositions comprises an additional
cancer antigen. The additional antigen can be any of those known in the art or described
herein, including, but not d to, mutated Ras, carcinoembryonic n (CEA), and
MUC-l.
In another embodiment of the invention, a method to treat cancer includes the
following steps: (a) administering to an individual who has cancer a first
immunotherapeutic composition comprising a yeast vehicle and a d Ras n; (b)
administering to the individual of (a) a second immunotherapeutic composition
comprising a yeast e and an antigen selected from the group consisting of
carcinoembryonic antigen (CEA) and mucin-l (MUC-l); and (c) administering to the
individual of (a) and (b) a third therapeutic composition comprising a yeast
vehicle and a Brachyury antigen. One or more of the steps of administration in (a), (b) and
(c) can be med concurrently, or sequentially. Steps may be repeated as needed to
treat a particular individual’s cancer, and the cancer ns can be modified before or
during treatment to specifically address the ular individual’s cancer.
In the method of the t invention, compositions and therapeutic
compositions can be administered to animal, including any vertebrate, and particularly to
any member of the Vertebrate class, Mammalia, including, without limitation, primates,
rodents, ock and domestic pets. Livestock e mammals to be consumed or that
produce useful products (e.g., sheep for wool production). Mammals to treat or protect
utilizing the invention include humans, man primates, dogs, cats, mice, rats, goats,
sheep, cattle, horses and pigs.
An “individual” is a vertebrate, such as a mammal, including without
limitation a human. s e, but are not limited to, farm animals, sport animals,
pets, primates, mice and rats. The term “individual” can be used interchangeably with the
term “animal”, “subject” or “patient”.
General Techniques Useful in the Invention
The practice of the present invention will employ, unless otherwise indicated,
conventional techniques of molecular biology (including recombinant techniques),
microbiology, cell biology, biochemistry, nucleic acid chemistry, and logy, which
are well known to those skilled in the art. Such techniques are explained fully in the
literature, such as, Methods of Enzymology, Vol. 194, Guthrie et al., eds., Cold Spring
Harbor Laboratory Press (1990); Biology and activities of yeasts, Skinner, et al., eds.,
Academic Press (1980); s in yeast genetics : a tory course manual, Rose et
al., Cold Spring Harbor Laboratory Press (1990); The Yeast Saccharomyces: Cell Cycle
and Cell Biology, Pringle et al., eds., Cold Spring Harbor Laboratory Press (1997); T_he
Yeast Saccharomyces: Gene Expression, Jones et al., eds., Cold Spring Harbor Laboratory
Press (1993); The Yeast Saccharomyces: Genome Dynamics, Protein Synthesis, and
Energetics, Broach et al., eds., Cold Spring Harbor Laboratory Press (1992); Molecular
Cloning: A Laboratogy , second edition (Sambrook et al., 1989) and Molecular
Cloning: A Laboratory Manual, third n ook and Russel, 2001), (jointly
referred to herein as “Sambrook”); Current Protocols in Molecular Biology (F.M. Ausubel
et al., eds., 1987, including supplements through 2001); PCR: The Polymerase Chain
Reaction, s et al., eds., 1994); Harlow and Lane , Antibodies, A Laboratogy
Manual, Cold Spring Harbor Publications, New York; Harlow and Lane (1999) Mg
Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring
Harbor, NY (jointly ed to herein as “Harlow and Lane”), Beaucage et al. eds.,
Current Protocols in c Acid Chemistgy, John Wiley & Sons, Inc., New York, 2000);
Casarett and Doull’s Toxicology The Basic Science of Poisons, C. Klaassen, ed., 6th
edition (2001), and Vaccines, S. n, W. Orenstein, and P. Offlt, eds., Fifth n
General Definitions
A “TARMOGEN®” (GlobeImmune, Inc., Louisville, Colorado) generally
refers to a yeast vehicle expressing one or more heterologous antigens extracellularly (on
its surface), intracellularly (internally or lically) or both extracellularly and
intracellularly. TARMOGEN®s have been generally described (see, e. g., US. Patent No.
,830,463). Certain yeast-based immunotherapy compositions, and methods of making
and generally using the same, are also described in detail, for example, in US. Patent No.
,830,463, US. Patent No. 7,083,787, US. Patent No. 7,736,642, Stubbs et al., Nat. Med.
7:625-629 (2001), Lu et al., Cancer ch 64:5084-5088 (2004), and in Bernstein et al.,
Vaccine 2008 Jan 24;26(4):509-21, each of Which is incorporated herein by reference in its
entirety.
As used herein, the term "analog" refers to a chemical compound that is
structurally similar to another compound but differs slightly in composition (as in the
replacement of one atom by an atom of a different element or in the presence of a
particular functional group, or the replacement of one onal group by another
functional . Thus, an analog is a compound that is similar or comparable in function
and appearance, but has a different structure or origin With respect to the reference
compound.
The terms "substituted", "substituted derivative" and "derivative", When used
to describe a compound, means that at least one en bound to the unsubstituted
compound is replaced with a different atom or a chemical moiety.
Although a derivative has a similar physical ure to the parent compound,
the derivative may have ent chemical and/or ical properties than the parent
compound. Such ties can include, but are not limited to, increased or decreased
activity of the parent compound, new activity as compared to the parent compound,
enhanced or decreased bioavailability, enhanced or decreased efficacy, enhanced or
decreased stability in vitro and/or in vivo, and/or enhanced or decreased absorption
properties.
In general, the term "biologically active" indicates that a nd (including
a protein or peptide) has at least one detectable actiVity that has an effect on the metabolic,
physiological, chemical, or other processes of a cell, a tissue, or an organism, as measured
or observed in viva (i.e., in a natural physiological environment) or in vitro (i.e., under
laboratory conditions).
According to the present invention, the term “modulate” can be used
interchangeably with “regulate” and refers generally to upregulation or downregulation of
a particular activity. As used herein, the term “upregulate” can be used generally to
describe any of: ation, initiation, increasing, ting, boosting, ing,
enhancing, amplifying, promoting, or providing, with respect to a ular ty.
Similarly, the term “downregulate” can be used generally to describe any of: decreasing,
reducing, inhibiting, ameliorating, diminishing, ing, blocking, or preventing, with
respect to a particular activity.
In one embodiment of the present invention, any of the amino acid sequences
described herein can be produced with from at least one, and up to about 20, additional
heterologous amino acids flanking each of the C- and/or N—terminal ends of the ed
amino acid sequence. The resulting protein or polypeptide can be referred to as
"consisting essentially of‘ the specified amino acid sequence. According to the present
invention, the heterologous amino acids are a sequence of amino acids that are not
naturally found (i.e., not found in nature, in vivo) flanking the specified amino acid
sequence, or that are not related to the function of the specified amino acid ce, or
that would not be encoded by the nucleotides that flank the naturally occurring nucleic
acid sequence encoding the specified amino acid ce as it occurs in the gene, if such
nucleotides in the naturally occurring sequence were ated using standard codon
usage for the organism from which the given amino acid sequence is derived. Similarly,
the phrase "consisting essentially of', when used with nce to a nucleic acid sequence
herein, refers to a nucleic acid sequence encoding a specified amino acid sequence that can
be flanked by from at least one, and up to as many as about 60, onal heterologous
nucleotides at each of the 5' and/or the 3' end of the nucleic acid sequence encoding the
specified amino acid sequence. The logous nucleotides are not naturally found (i.e.,
not found in nature, in viva) flanking the nucleic acid sequence encoding the specified
amino acid sequence as it occurs in the natural gene or do not encode a protein that
imparts any additional function to the n or changes the function of the protein having
the specified amino acid sequence.
ing to the present invention, the phrase "selectively binds to" refers to
the ability of an antibody, antigen-binding fragment or binding partner of the present
invention to preferentially bind to specified proteins. More specifically, the phrase
"selectively binds" refers to the specific binding of one protein to another (e.g., an
antibody, nt f, or binding partner to an antigen), wherein the level of binding,
as measured by any standard assay (e.g., an immunoassay), is statistically significantly
higher than the background control for the assay. For example, when performing an
immunoassay, controls typically include a reaction well/tube that n antibody or
antigen binding nt alone (i.e., in the absence of antigen), wherein an amount of
reactiVity (e.g., non-specific binding to the well) by the antibody or antigen-binding
fragment f in the absence of the antigen is considered to be background. Binding
can be ed using a variety of methods standard in the art ing enzyme
immunoassays (e.g., ELISA, immunoblot assays, etc.).
General nce to a protein or polypeptide used in the present invention
includes full-length proteins, near full-length proteins (defined above), or any fragment,
domain (structural, functional, or immunogenic), conformational epitope, or a homologue
or variant of a given protein. A fusion protein may also be generally referred to as a
n or polypeptide. An isolated protein, according to the present invention, is a protein
(including a polypeptide or peptide) that has been removed from its natural milieu (i.e.,
that has been subject to human manipulation) and can include purified proteins, partially
d proteins, recombinantly produced ns, and synthetically produced proteins,
for example. As such, "isolated" does not reflect the extent to which the protein has been
purified. Preferably, an isolated protein of the present invention is ed
recombinantly. According to the t invention, the terms "modification" and
"mutation" can be used interchangeably, particularly with regard to the
modifications/mutations to the amino acid sequence of proteins or portions thereof (or
nucleic acid sequences) described herein.
As used herein, the term "homologue" or “variant” is used to refer to a protein
or peptide which differs from a reference protein or peptide (i.e., the "prototype" or "wild-
type" protein) by minor modifications to the reference protein or peptide, but which
maintains the basic protein and side chain structure of the naturally occurring form. Such
changes include, but are not limited to: s in one or a few amino acid side chains;
changes one or a few amino acids, ing deletions (e. g., a truncated version of the
protein or peptide) insertions and/or substitutions; changes in stereochemistry of one or a
few atoms; and/or minor derivatizations, including but not limited to: methylation,
glycosylation, phosphorylation, acetylation, myristoylation, ation, palmitation,
ion and/or addition of glycosylphosphatidyl inositol. A homologue or variant can
have enhanced, decreased, or substantially similar properties as compared to the reference
protein or peptide. A gue or variant can include an t of a protein or an
antagonist of a protein. Homologues or variants can be produced using techniques known
in the art for the production of proteins including, but not limited to, direct ations
to the isolated reference protein, direct protein synthesis, or modifications to the nucleic
acid sequence encoding the protein using, for example, classic or recombinant DNA
techniques to effect random or targeted mutagenesis, resulting in the encoding of a protein
variant. In addition, naturally occurring variants of a reference protein may exist (e.g.,
isoforms, allelic variants, or other natural variants that may occur from individual to
individual) and may be isolated, produced and/or utilized in the invention.
A homologue or variant of a given protein may comprise, consist ially
of, or consist of, an amino acid sequence that is at least about 45%, or at least about 50%,
or at least about 55%, or at least about 60%, or at least about 65%, or at least about 70%,
or at least about 75%, or at least about 80%, or at least about 85%, or at least about 86%
identical, or at least about 87% cal, or at least about 88% identical, or at least about
89% identical, or at least about 90%, or at least about 91% cal, or at least about 92%
identical, or at least about 93% identical, or at least about 94% identical, or at least about
95% identical, or at least about 96% identical, or at least about 97% identical, or at least
about 98% identical, or at least about 99% identical (or any percent identity between 45%
and 99%, in whole integer increments), to the amino acid ce of the reference
protein (e. g., an amino acid ce ed , or the amino acid sequence of a
specified protein). In one embodiment, the homologue or variant comprises, consists
ially of, or consists of, an amino acid sequence that is less than 100% identical, less
than about 99% identical, less than about 98% cal, less than about 97% identical, less
than about 96% identical, less than about 95% identical, and so on, in increments of 1%, to
less than about 70% identical to the amino acid sequence of the reference protein.
As used herein, unless otherwise specified, reference to a percent (%) identity
refers to an evaluation of homology which is med using: (1) a Basic Local
Alignment Search Tool (BLAST) basic homology search using blastp for amino acid
searches and blastn for nucleic acid searches with rd default parameters, wherein the
query sequence is filtered for low complexity regions by default (such as described in
Altschul, S.F., Madden, T.L., Schaaffer, A.A., Zhang, J ., Zhang, 2., Miller, W. & Lipman,
D]. (1997) "Gapped BLAST and PSI-BLAST: a new generation of protein database
search programs." Nucleic Acids Res. 25:3389-3402, incorporated herein by reference in
its entirety); (2) a BLAST ent of two sequences (e. g., using the parameters
bed below); (3) and/or PSI-BLAST with the standard default parameters (Position-
Specific Iterated BLAST. It is noted that due to some differences in the standard
parameters between Basic BLAST and BLAST for two sequences, two specific sequences
might be recognized as having significant homology using the BLAST program, whereas a
search performed in Basic BLAST using one of the sequences as the query ce may
not identify the second sequence in the top matches. In addition, PSI-BLAST provides an
automated, easy-to-use version of a "profile" search, which is a sensitive way to look for
sequence homologues. The program first performs a gapped BLAST database search. The
PSI-BLAST program uses the information from any significant alignments returned to
construct a position-specific score matrix, which replaces the query sequence for the next
round of se searching. Therefore, it is to be understood that percent identity can be
determined by using any one of these programs.
Two specific sequences can be aligned to one another using BLAST as
described in Tatusova and Madden, (1999), "Blast 2 sequences - a new tool for comparing
n and nucleotide sequences", FEMS Microbiol Lett. 174:247-250, orated
herein by reference in its ty. Such a sequence alignment is med in blastp or
blastn using the BLAST 2.0 algorithm to perform a Gapped BLAST search (BLAST 2.0)
n the two sequences allowing for the introduction of gaps (deletions and insertions)
in the resulting alignment. For purposes of clarity herein, a BLAST sequence alignment
for two ces is performed using the standard default parameters as follows.
For blastn, using 0 BLOSUM62 matrix:
Reward for match = l
Penalty for mismatch = -2
Open gap (5) and extension gap (2) penalties
gap x_dropoff (50) expect (10) word size (ll) filter (on)
For , using 0 BLOSUM62 matrix:
Open gap (ll) and extension gap (1) penalties
gap x_dropoff (50) expect (10) word size (3) filter (on).
An isolated nucleic acid molecule is a nucleic acid molecule that has been
removed from its natural milieu (i.e., that has been t to human manipulation), its
natural milieu being the genome or chromosome in which the nucleic acid molecule is
found in . As such, "isolated" does not necessarily reflect the extent to which the
nucleic acid molecule has been d, but indicates that the molecule does not include
an entire genome or an entire chromosome or a segment of the genome containing more
than one gene, in which the nucleic acid molecule is found in nature. An isolated c
acid molecule can include a complete gene. An isolated nucleic acid molecule that
includes a gene is not a fragment of a chromosome that includes such gene, but rather
includes the coding region and regulatory regions associated with the gene, but no
additional genes that are naturally found on the same chromosome. An ed nucleic
acid molecule may also include portions of a gene. An isolated c acid molecule can
also include a specified nucleic acid ce flanked by (i.e., at the 5' and/or the 3' end of
the sequence) additional nucleic acids that do not normally flank the specified nucleic acid
sequence in nature (i.e., heterologous sequences). Isolated nucleic acid molecule can
include DNA, RNA (e. g., mRNA), or derivatives of either DNA or RNA (e. g., cDNA).
Although the phrase "nucleic acid molecule" primarily refers to the physical nucleic acid
molecule and the phrase ic acid sequence" primarily refers to the sequence of
nucleotides on the nucleic acid molecule, the two phrases can be used interchangeably,
especially with respect to a nucleic acid molecule, or a nucleic acid sequence, being
capable of ng a protein or domain of a protein.
A recombinant nucleic acid le is a molecule that can e at least
one of any nucleic acid sequence encoding any one or more proteins described herein
operatively linked to at least one of any ription control sequence capable of
effectively regulating sion of the nucleic acid molecule(s) in the cell to be
transfected. Although the phrase "nucleic acid molecule" primarily refers to the physical
c acid molecule and the phrase "nucleic acid sequence" primarily refers to the
sequence of nucleotides on the nucleic acid molecule, the two phrases can be used
interchangeably, especially with respect to a nucleic acid molecule, or a nucleic acid
sequence, being capable of encoding a protein. In addition, the phrase "recombinant
molecule" primarily refers to a nucleic acid molecule operatively linked to a ription
control sequence, but can be used interchangeably with the phrase "nucleic acid molecule"
which is administered to an animal.
A recombinant nucleic acid molecule es a recombinant vector, which is
any nucleic acid sequence, typically a heterologous sequence, which is operatively linked
to the isolated nucleic acid le encoding a fusion protein of the present invention,
which is capable of enabling recombinant production of the fusion protein, and which is
e of delivering the nucleic acid molecule into a host cell according to the present
invention. Such a vector can contain nucleic acid sequences that are not naturally found
adjacent to the isolated nucleic acid molecules to be ed into the vector. The vector
can be either RNA or DNA, either prokaryotic or eukaryotic, and preferably in the present
invention, is a plasmid useful for transfecting yeast. Recombinant vectors can be used in
the cloning, sequencing, and/or otherwise manipulating of nucleic acid molecules, and can
be used in delivery of such molecules (e.g., as in a DNA composition or a viral vector-
based composition). Recombinant vectors are preferably used in the expression of nucleic
acid molecules, and can also be referred to as sion vectors. Preferred inant
vectors are capable of being expressed in a transfected host cell, such as a yeast.
In a recombinant molecule of the t invention, nucleic acid molecules are
operatively linked to expression s containing regulatory sequences such as
transcription control sequences, ation l sequences, origins of replication, and
other regulatory sequences that are compatible with the host cell and that control the
expression of nucleic acid molecules of the present invention. In particular, recombinant
molecules of the present invention e nucleic acid molecules that are operatively
linked to one or more expression control sequences. The phrase "operatively linked"
refers to linking a nucleic acid molecule to an expression control sequence in a manner
such that the molecule is expressed when transfected (i.e., transformed, transduced or
transfected) into a host cell.
] According to the present invention, the term “transfection” is used to refer to
any method by which an exogenous nucleic acid molecule (i.e., a inant nucleic acid
molecule) can be inserted into a cell. The term "transformation" can be used
interchangeably with the term "transfection" when such term is used to refer to the
introduction of nucleic acid les into microbial cells, such as algae, ia and
yeast. In microbial systems, the term "transformation" is used to describe an inherited
change due to the acquisition of exogenous nucleic acids by the rganism and is
essentially synonymous with the term "transfection.’ ore, transfection techniques
include, but are not limited to, transformation, chemical treatment of cells, particle
bombardment, electroporation, njection, lipofection, adsorption, infection and
protoplast fusion.
The following experimental results are provided for purposes of illustration
and are not intended to limit the scope of the invention.
EXAMPLES
Example 1
] The following example describes the production of a yeast-Brachyury
immunotherapeutic composition.
] In this experiment, yeast (Saccharomyces cerevisiae) were engineered to
s human Brachyury under the control of the copper-inducible promoter, CUPI , or
the constitutive promoter, TEF2
, producing yeast-Brachyury immunotherapy compositions.
In each case, a fusion protein comprising a Brachyury antigen was produced as a single
polypeptide with the following sequence elements fused in frame from N— to C-terminus,
represented by SEQ ID NO:8 (1) an N—terminal peptide to impart resistance to
proteasomal degradation and stabilize expression (positions 1 to 6 of SEQ ID NO:8, the
peptide sequence also represented herein by SEQ ID ; 2) amino acids 2-435 of
SEQ ID NO:6, SEQ ID NO:6 representing a near full-length human Brachyury protein
(positions 7-440 of SEQ ID NO:8); and (3) a hexahistidine tag (positions 441-446 of SEQ
ID NO:8). The amino acid sequences used in this fusion protein can be modified by the
use of additional or alternate amino acids flanking either end of the Brachyury antigen, if
desired, and shorter portions of the Brachyury antigen may also be used. A nucleic acid
sequence ng the fusion protein of SEQ ID NO:8 (codon optimized for yeast
expression) is represented herein by SEQ ID NO:7.
Briefly, DNA encoding a full length human Brachyury n from a
Brachyury-PCRII plasmid ed by the National Cancer Institute (Dr. y Schlom)
was ied using PCR, and then inserted at EcoRI and Spel cloning sites behind the
CUP] er (vector pGI-lOO) or the TEF2 promoter (vectors pluOll or pGI-172) in
yeast 2 um expression vectors. Nucleotide sequences encoding the N—terminal
stabilization e, MADEAP (SEQ ID NO: 1 l) and a C-terminal hexahistidine peptide
were also added to the plasmid vector to encode the complete fusion protein ented
by SEQ ID NO:8. The resulting plasmids were transformed into DH50L for plasmid
storage, and into Saccharomyces cerevisiae W3030L for production of the yeast-Brachyury
immunotherapeutic compositions.
Transformation into Saccharomyces cerevisiae was performed by m
acetate/polyethylene glycol transfection, and primary transfectants were selected on solid
minimal plates lacking Uracil (UDM; uridine t medium). Colonies were selected
by growing in U2 (uridine dropout medium) or UL2 (uridine and leucine dropout medium)
medium at 30° C.
The yeast-Brachyury immunotherapy composition comprising a
cleotide encoding the human Brachyury fusion protein represented by SEQ ID
NO:8 under the control of the CUP] promoter is also referred to herein as GI-6301. The
Brachyury immunotherapy composition comprising a polynucleotide encoding the
human Brachyury fusion protein represented by SEQ ID NO:8 under the control of the
TEF2 promoter (in vector plu011) is also referred to herein as GI-6302. The yeast
Brachyury therapy composition comprising a polynucleotide encoding the human
Brachyury fusion protein represented by SEQ ID NO:8 under the control of the TEF2
promoter (in vector pGI-172) is also referred to herein as GI-6303.
Liquid es lacking uridine (U2) or lacking uridine and leucine (UL2)
were inoculated using the plates and starter cultures described above, and were grown for
20h at 30°C, 250 rpm. pH buffered media ning 4.2g/L of Bis-Tris (BT-U2; BT-
UL2) were also inoculated to evaluate yeast-Brachyury immunotherapeutics produced
under neutral pH manufacturing conditions (data not shown). Primary cultures were used
to inoculate final cultures of the same formulation.
Recipe for U2 liguid media:
0 15g/L of glucose
0 6.7 g/L of Yeast nitrogen base containing ammonium sulfate
0 0.04 g/L each of histidine, phan, adenine and 0.06 g/L of leucine
Recipe for UL2 liguid media:
0 15g/L of glucose
0 6.7 g/L of Yeast nitrogen base containing ammonium sulfate
0 0.04 g/L each of histidine, tryptophan, and adenine
In initial experiments comparing yeast-Brachyury immunotherapeutic
compositions under the control of different promoters, CUPI-driven (inducible
expression) Brachyury expression was initiated by the addition of 0.5 mM copper
sulfate after the Brachyury culture reached a density of approximately 0.2 Y.U./ml,
and was continued until the e reached a density of 0.5-1.5 Y.U. (yeast-Brachyury
doubled only about 1-1.5 after the addition of copper sulfate, but a large amount of
Brachyury n was produced by the . TEF2-driven yeast-Brachyury expression
is constitutive, and growth of these cells was ued until the cultures reached a density
of between 1.1 to 4.0 Y.U./ml. The cells from each culture were then harvested, washed
and heat-killed at 56°C for 1 hour in PBS. Live cells from each culture were also
processed for comparison.
After heat-kill of the cultures, the cells were washed three times in PBS. Total
n expression was measured by a TCA precipitation/nitrocellulose binding assay and
by Western blot using an anti-his tag monoclonal antibody and an anti-Brachyury antibody
(Abcam, Cambridge, MA). Protein content was quantified using semi-quantitative digital
imaging methods.
The s of the initial sion experiments (data not shown)
demonstrated that each of the yeast-Brachyury immunotherapy compositions of the
invention expressed the ury fusion protein, z'.e., using either the CUPI promoter or
the TEF2 promoter, and expression was detected using either media (U2 and UL2). In
addition, n expression was detectable in both heat-killed and live yeast cells (data
not shown). Brachyury expression was significantly higher in the yeast-Brachyury
immunotherapeutic composition comprising the CUP] promoter (GI-6301) and so this
composition was selected for further studies, including expression optimization and for in
vitro and in vivo experiments (see Examples below).
Fig. 1A shows expression of Brachyury in GI-6301 using both U2 and UL2
media using the anti-Brachyury dy for detection. Control yeast sing a non-
Brachyury antigen did not stain with the dy. Fig. 1B shows expression of
Brachyury in the same GI-6301 ations, using anti-His to identify the hexahistidine
tag on the Brachyury fusion n. Control yeast expressing a non-Brachyury antigen
but having a hexahistidine tag is also shown. These results showed good Brachyury
expression using either media, although expression in UL2 media was significantly higher.
Example 2
The following example describes the identification of conditions for antigen
expression and manufacturing of the yeast-Brachyury immunotherapeutic composition,
GI-6301.
To determine the optimum density for copper induction of GI-6301 n
expression, starter and intermediate cultures of 1 were prepared using the standard
growth conditions in UL2 media described in Example 1 above. Aliquots of the culture
were then d to 0.5 Y.U./ml, 1.0 Y.U./ml and 1.5 Y.U./ml and incubated at 30°C for 1
hour. 0.5 mM CuSO4 was added to the cultures to induce Brachyury sion, and
culturing was continued. Cells were collected and counted at 6 hours and 14 hours for
measurement of cell density. 20 Y.U. of heat-killed yeast from each condition was lysed,
total protein was measured, and Western blots were generated using anti-His.
Cell Density
(Y.U.lm|)
As shown in Table l, yeast only doubled about 1 time after copper induction
(other experiments showed up to 1.5X doubling), and cell density and viability (not
shown) decreased after 6 hours of copper induction. Fig. 2 shows that all three induction
ies ed in significant expression of Brachyury, with a trend toward higher
ury expression at the higher induction densities. However, additional experiments
using induction starting densities of 2.1 Y.U./ml and 2.8 Y.U./ml and 375 uM CuSO4
showed that protein expression began to decrease as the y of the cultures at the start
of copper induction increased, and did not significantly improve after about 6-8 hours
(data not shown).
] Next, the effect of the amount of CuSO4 on Brachyury expression was
investigated. 1 was grown from starter and intermediate cultures in UL2 media as
described in Example 1. ts of the culture were then diluted to 1.0 Y.U./ml and
incubated at 30°C for 1 hour. CuSO4 was added to each culture at a concentration of
either 375 uM or 500 uM, and induction of protein expression was allowed to proceed to
s time points (2 hrs, 4 hrs, 6 hrs, 8 hrs, 24 hrs), at which point the cells were
harvested, heat-killed, and processed for evaluation of protein expression using anti-His
Western blots as described above. While both concentrations of CuSO4 resulted in good
sion of Brachyury, protein expression using 375 uM appeared to be slightly better,
particularly at later time points (data not shown).
Accordingly, for CUPI-driven yeast-Brachyury (inducible expression), the
inventors discovered that induction of antigen expression at mid-log phase growth of the
yeast was optimal for antigen tion. For production of the yeast-Brachyury
immunotherapeutic composition (GI-6301) used in the following Examples, cells were
grown in UL2 media as described in Example 1 to between 1 and 2 Y.U./ml, and were
then induced by the on of 0375-05 mM copper sulfate for up to 6-8 hours at 30°C,
250 rpm. Cells were harvested, washed and heat killed at 56°C for 1h in PBS.
Example 3
The following example describes the construction and production of an
additional yeast-Brachyury immunotherapeutic composition, where the Brachyury n
contains a T cell agonist epitope.
In this experiment, yeast (Saccharomyces cerevisiae) were engineered to
express a human Brachyury antigen that is a near-full-length Brachyury protein
comprising the T cell epitope WLLPGTSTV (SEQ ID NO: 13), which is an agonist epitope.
The native Brachyury T cell epitope, present in SEQ ID NO:6 or 8, for e, is
STL (SEQ ID NO:l2). The human Brachyury agonist antigen was expressed
under the control of the copper-inducible promoter, CUP], producing a yeast-Brachyury
immunotherapy composition. More particularly, a fusion protein comprising a Brachyury
agonist antigen (i.e., a Brachyury antigen containing at least one agonist epitope) was
produced as a single polypeptide with the following sequence ts fused in frame
from N- to C-terminus, ented by SEQ ID NO:20 (1) an N-terminal peptide to impart
resistance to proteasomal degradation and stabilize expression (positions 1 to 6 of SEQ ID
NO:20, the peptide sequence also represented herein by SEQ ID NO:ll); 2) amino acids
2-435 of SEQ ID NO:l8 (represented by positions 7-440 of SEQ ID NO:20; SEQ ID
NO:l8 represents a full-length human Brachyury agonist protein having a single amino
acid substitution at position 254 as compared to wild-type ury protein); and (3) a
hexahistidine tag (positions 441-446 of SEQ ID . The agonist epitope (SEQ ID
NO:l3) is located at positions 251 to 259 of SEQ ID NO:20 (positions 246 to 254 of SEQ
ID NO:l8). The amino acid sequences used in this fusion protein can be modified by the
use of additional or alternate amino acids flanking either end of the ury antigen, if
desired, and shorter portions of the ury antigen may also be used. A nucleic acid
sequence encoding the fusion protein of SEQ ID NO:20 (codon optimized for yeast
sion) is represented herein by SEQ ID NO: 19.
, DNA encoding the near full-length human Brachyury protein as
bed in e 1 (i.e., full-length Brachyury minus the N-terminal methionine),
modified by site directed mutagenesis to introduce a substitution of a valine for the e
at position 254 with respect to the full-length Brachyury protein, was amplified using PCR,
and then inserted at EcoRI and Spel cloning sites behind the CUP] promoter (vector pGI-
100) in yeast 2 um sion vectors. Nucleotide sequences encoding the N—terminal
stabilization peptide, MADEAP (SEQ ID NO: 1 l) and a C-terminal hexahistidine peptide
were also added to the plasmid vector to encode the complete fusion protein represented
by SEQ ID NO:20. The resulting plasmids were transformed into DHSu for plasmid
storage, and into Saccharomyces cerevisiae W3030L for production of the yeast-Brachyury
immunotherapeutic composition.
Transformation into Saccharomyces cerevisiae was performed by m
acetate/polyethylene glycol transfection, and primary transfectants were ed on solid
minimal plates lacking Uracil (UDM; uridine dropout medium). Colonies were selected
by growing in UL2 (uridine and leucine dropout medium) medium at 30° C.
] The Brachyury immunotherapy composition comprising a
polynucleotide encoding the human Brachyury agonist fusion protein represented by SEQ
ID NO:20 under the control of the CUP] promoter is also referred to herein as GI-6305.
GI-6305 cells were grown in UL2 media as described in Example 1 to
between 1 and 2 Y.U./ml, and were then induced by the addition of 0375-05 mM copper
sulfate for up to 6-8 hours at 30°C, 250 rpm, using the ions developed by the
inventors for GI-6301 as described in Example 2. Cells were harvested, washed and heat
killed at 56°C for lh in PBS.
After heat-kill of the cultures, the cells were washed three times in PBS. Total
protein expression was ed by a TCA precipitation/nitrocellulose binding assay and
by Western blot using an anti-his tag monoclonal antibody and an anti-Brachyury antibody
(Abcam, Cambridge, MA). Protein content was quantified using semi-quantitative digital
imaging methods.
Fig. 1C shows the robust sion of ury agonist antigen in GI-6305
using anti-His to identify the hexahistidine tag on the Brachyury fusion protein. The
imate antigen content for GI-6305 grown in UL2 medium in this experiment was
>22615 ng/Y.U.
Example 4
] The following example demonstrates the expansion of Brachyury-specific
T cells using a yeast-Brachyury immunotherapeutic composition of the invention.
To ine whether T cells from normal donors were capable of generating
T cells that are specific for Brachyury antigen, dendritic cells (DCs) were prepared from
the peripheral blood mononuclear cells (PBMCs) of two normal donors. Briefly, isolated
PBMCs were cultured for 5-days in the presence of GM-CSF and IL-4, and were
subsequently incubated with Control Yeast (also d “YVEC”, which is a
Saccharomyces cerevisiae yeast that is transformed with an empty vector, or vector that
does not n an antigen-encoding ) or Brachyury Yeast 01, described in
Examples 1 and 2 above), at a ratio of yeast:DCs= l:l. After 48-hours co-culture, the DCs
were used as APCs for stimulation of autologous T cells. Each cycle of stimulation,
ated as IVS (in vitro stimulation), consisted of 3 days culture in absence of IL-2,
following by 4 onal days in the presence of recombinant IL-2 (20 U/ml). At the end
of IVS 2, T cells were stained with a control tetramer or a tetramer specific for the
Brachyury peptide Tp2 (WLLPGTSTL, positions 246 to 254 of SEQ ID NO:2 or SEQ ID
NO:6). Table 2 shows the percentage of CD8+ T cells that stained positive with each
tetramer.
Table 2
Donor Stimulation Control Brachyury
Tetramer Tetramer
Control Yeast
07706
Brachyury Yeast
Control Yeast
17663
Brachyury Yeast
In a second experiment, dendritic cells (DCs) were prepared from PBMCs of
nine normal donors using a 5-day e in presence of GM-CSF and IL-4, subsequently
incubated with Brachyury yeast (GI-6301), at a ratio yeast:DCs= 1:1, as described above.
After rs in ture, the DCs were used as APCs for stimulation of autologous T
cells. Each cycle of IVS was performed as described above. At the end of IVS 2, T cells
were stained with a control er or a tetramer specific for the Brachyury peptide Tp2.
Table 3 shows the percentage of CD8+ T cells that stained positive with each Tetramer.
Table 3
ury Yeast
Brachyury Yeast
ury Yeast
Brachyury Yeast
Brachyury Yeast
Brachyury Yeast
Brachyury Yeast
Brachyury Yeast
Brachyury Yeast
The results in Tables 2 and 3 show that stimulation of normal donor T cells
with a Brachyury immunotherapeutic of the ion increases the percentage of
tetramer-positive CD8+ T cells in a majority of the normal , as compared to controls,
indicating that normal human T cells have the capacity to recognize Brachyury as an
immunogen.
Example 5
The following example demonstrates the ability of a yeast-Brachyury
immunotherapeutic composition to generate Brachyury-specific CTLs from normal donor
PBMCs that lyse ury-expressing targets.
In this experiment, Brachyury-specific T cells from three of the normal donors
from Table 2 above were expanded in vitro using DCs incubated with Brachyury yeast
(GI-6301) for 2 cycles of IVS (as described in Example 4). A third IVS was carried out
with DCs matured in presence of CD40L and pulsed with the Brachyury-specific Tp2
peptide (WLLPGTSTL, positions 246 to 254 of SEQ ID NO:2 or SEQ ID NO:6). At day
, CD8+ T cells were isolated and used in an overnight cytotoxic T lymphocyte (CTL)
assay against SW480 2+ / Brachyury high) and MCF7 (HLA-A2+ / Brachyury
low ) tumor cell targets, at the indicated effector:target (ET) ratios (see Fig. 3). Shown in
Table 4 is the percentage of CD8+ T cells that stained positive with a control tetramer
versus a Brachyury-specific Tp2 tetramer.
Table 4
Brachyury
Yeast/Tp2
17663 Brachyury 0.11 0.65
Yeast/Tp2
26532 Brachyury 0.05 0.11
Yeast/Tp2
Figs. 3A (donor 07706), 3B (donor 17663) and 3C (donor 26532) show that
PBMCs from two out of three normal donors were capable of generating CD8+ CTLs that
could kill targets expressing Brachyury. Taken together, these data demonstrate that
Brachyury immunotherapeutic compositions can te Brachyury-specific CTLs
that are capable of killing a Brachyury-expressing tumor cell.
In order to show that yeast-Brachyury therapy can induce Brachyury-
specific CTLs in the absence of pulsing with a specific peptide (i.e., by generating CTLs
against potentially multiple different CTL epitopes), additional experiments were
performed using normal donor T cells ed in vitro using only the yeast-Brachyury
immunotherapeutic ition, GI-6301 (i.e., no peptide pulse). Briefly, Brachyuryspecific
T cells from normal donor PBMCs (donor 19063) were expanded in vitro by
using DCs incubated with GI-6301 for 2 cycles of IVS (as described in Example 4). At
day 5, CD8+ T cells were isolated and used in an overnight CTL assay against SW480
(HLA-A2 positive/Brachyury high) and H226 (HLA-A2 negative/Brachyury high) tumor
cells, at an or:target (ET) ratio of 15:1. Fig. 4A shows the percentage of c
lysis of SW480 and H226 tumor cells. Fig. 4B shows the expression of Brachyury mRNA
relative to that of GAPDH in SW480 and H226 tumor cells by ime RT-PCR. These
experiments further demonstrate that yeast-Brachyury immunotherapeutic composition
can generate Brachyury-specific CTLs that are capable of killing a Brachyury-expressing
tumor cell.
Example 6
The following example demonstrates that a yeast-Brachyury ition of
the invention can expand Brachyury-specific T cells from cancer ts.
In this experiment, DCs were prepared from the PBMCs of two breast cancer
patients, post-vaccination with viral vector vaccines comprising CEA and MUC-l antigens.
The DCs were prepared in a 5-day culture in presence of GM-CSF and IL-4 as described
in Example 4, followed by incubation in presence of Brachyury yeast (GI-6301) at a ratio
of yeast:DCs= 1:1. After 48-hours co-culture, the DCs were used as APCs for stimulation
of autologous T cells. Each cycle of IVS ted of 3 days in absence of IL-2, following
by 4 additional days in presence of 20 U/ml of recombinant IL-2. Shown in Table 5 is the
percentage of CD8+ T cells (IVSl) that stained positive with a control tetramer or a
tetramer specific for the ury peptide Tp2.
Table 5
Breast Pt 01 Brachyury Yeast 0.11 0.42
Breast Pt 10 Brachyury Yeast 0.23 0.91
The results in Table 5 demonstrate that stimulation of T cells from breast
cancer donors with a yeast-Brachyury immunotherapeutic of the invention increases the
percentage of tetramer-positive CD8+ T cells in a majority of the donors, as compared to
controls, indicating that T cells from donors with ongoing cancer have the capacity to
recognize Brachyury as an immunogen.
Example 7
The following Example demonstrates the generation of CD4+ T cell responses
specific for Brachyury in viva using yeast-Brachyury immunotherapy.
In this ment, C57BL/6 mice were vaccinated weekly for a total of 4
times with 4 YU of yeast-hBrachyury (GI-6301), administered at four separate injection
sites at 1 YU per site). Two weeks after the final boost, the mice were sacrificed and CD4+
T cells were purified and assayed for proliferation in presence of various concentrations of
Brachyury d n (obtained from insect cells). As a control, B-Gal was used at
40 ug/ml.
The results showing the proliferation of CD4+ T cells ed from the spleens
of animals vaccinated with yeast-control (YVEC, see e 4) and yeast-hBrachyury
(GI-6301) are shown in Fig. 5. Fig. 5 shows that zation with yeast-Brachyury (GI-
6301) generates ury-specific CD4+ T cells.
The following example demonstrates that immunization with yeast-Brachyury
immunotherapeutic composition reduces Brachyury-expressing tumors in vivo.
In this experiment, C57BL/6 mice received 1 x 106 MC38-phBrachyury cells
(MC38 tumor cells expressing a recombinant human Brachyury) via the tail vein (day 0).
Four days post-tumor implantation, animals began receiving weekly vaccinations with
yeast control (YVEC, see Example 4) versus yeast-hBrachyury (GI-6301), administered at
a dose of lYU per site at four different sites (4YU total per dose). At day 40 umor
implantation, animals were sacrificed and the number of lung tumor nodules was
evaluated. Results from two combined ments are shown in Fig. 6. Table 6 shows
the mean lung tumor number (:: SEM) and the number (and percentage) of animals
bearing 2 5 lung nodules.
Table 6
Yeast-Control (YVEC) 4.1 i 1.2 7/15 (46.7%)
Brachyury (GI-6301) 1.9 i 0.5 2/15 )
The results in Fig. 6 and Table 6 demonstrate that stration of a yeast-
Brachyury immunotherapeutic composition of the invention is capable of reducing
Brachyury-expressing tumors in mice, as compared to mice receiving yeast alone (no
Brachyury antigen).
Example 9
The following example demonstrates the generation of ury-specific
CD4+ T cell responses in vitro using Brachyury immunotherapy in human peripheral
blood mononuclear cells (PBMCs) obtained from healthy donors.
In the following experiments, a full-length human Brachyury protein was
expressed in insect cells via baculovirus expression and uently purified.
Dendritic cells (DCs) were ed from PBMCs of healthy donors by 5-day
culture with GM-CSF and IL-4 and subsequently treated in vitro with yeast-control
(YVEC, see Example 4) or yeast-Brachyury (GI-6301, see Examples 1 and 2) (ratio
yeast:DCs = 1:1). After 48 hours, DCs were harvested, irradiated (30 Gy) and used for
stimulation of autologous PBMCs, at a ratio DC:PBMCs = 1:10. On day 3, IL-2 (10
U/ml) was added to the es. On day 7, stimulated T cells were harvested and
subsequently tested for IFN—y production in response to autologous, irradiated PBMCs
(ratio T cells: PBMCs = 1:3) alone or in the presence of 10 ug/ml of purified Brachyury
protein or control human serum albumin protein. Following 96 hours stimulation,
supematants were collected and evaluated for IFN—y levels by ELISA assay. A total of 9
healthy donors were evaluated, with 3/9 donors demonstrating ury-specific CD4+
T-cell responses post-stimulation in vitro with yeast-Brachyury-treated DCs. Results for 3
positive cases are presented in Table 7 (values indicate the levels of IFN-y in response to
Brachyury protein, after subtracting background levels induced by stimulation with control Human
Serum Albumin protein; for donor 3, two cycles of ation were performed prior to evaluating
response to Brachyury protein).
Table 7
Donor ID DC stimulation 6mm!)
1 Yeast-control 1500.0
Yeast-Brachyury 2950.0
2 control 13.4
Yeast-Brachyury 889.0
3 Yeast-control 17.4
Yeast-Brachyury 102.8
Six onal healthy donors were evaluated for CD4+ T cell responses to the
Brachyury protein, following in vitro stimulation with yeast-Brachyury (GI-630l)-treated
DCs by intracellular cytokine staining of IFN-y in CD4+ cells. tic cells were
prepared from PBMCs of healthy donors by 5-day culture with GMCSF and IL-4 and
subsequently treated in vitro with yeast-control (YVEC) or yeast-Brachyury (GI-6301)
(ratio yeast:DCs = 1:1). After 48 hours, the DCs were harvested, irradiated (30 Gy) and
used for stimulation of autologous PBMCs, at a ratio DC:PBMCs = 1:10. On day 3, IL-2
(10 U/ml) was added to the cultures. On day 7, stimulated T cells were harvested and
subsequently tested for IFN—y production in se to gous PBMCs (ratio T cells:
PBMCs = 1:3) alone or in the presence of 10 ug/ml of purified Brachyury n or
control human serum albumin protein. Following 2 hours stimulation, BD
GOLGISTOPTM Protein Transport Inhibitor (BD Biosciences) was added to the cultures.
Following 4 hours stimulation, cells were harvested, bilized, and stained for CD4
and IFN-y utilizing anti-CD4 PerCP-Cy5.5 and anti-IFN-y FITC antibodies (BD
ences). A total of 6 healthy donors were evaluated, with 2/6 donors demonstrating
Brachyury-specific CD4+ T-cell responses post-stimulation in vitro with Brachyury
treated DCs. Results for positive cases are shown in Table 8 (values indicate the percentage
of T cells that were aneously positive for CD4 and intracellular IFN—y in response to control
human serum albumin (HSA) or Brachyury protein, after subtracting ound levels induced
by stimulation with PBMCs alone).
Table 8
% CD4+IIFN-v+ cells
Number of
Donor
stlmulatlons In Vltro. . . . HSA Brachyury
4 1 0.07 0 24
2 0.00 1.00
Example 10
The following example demonstrates that a yeast-Brachyury immunotherapy
composition expressing a ury agonist antigen generates Brachyury-specific T cells
from a prostate cancer patient.
To generate a Brachyury-specific T-cell line, re autologous dendritic
cells (DCs) were exposed to the yeast-Brachyury immunotherapy ition known at
GI-6305 (see Example 3) at a ratio of DCs:GI-6305 = 1:1 for 48 hours, and subsequently
used as antigen presenting cells (APCs) to stimulate gous non-adherent cells at an
effector-to-APC ratio of 10:1. Cultures were incubated for 3 days at 37°C, in a humidified
atmosphere containing 5% C02, and subsequently supplemented with recombinant human
IL-2 at a concentration of 20 U/ml for an additional 7 days. The 10-day culture
constituted one in vitro stimulation (IVS) cycle. T cells were restimulated with GI
exposed autologous DCs as described above on day 11, to begin the next IVS cycle. GI-
6305-exposed autologous DCs were used as APCs for three IVS cycles. After the third
IVS, irradiated (23,000 rads) autologous EBV-transformed B cells, pulsed with an agonist
Brachyury peptide, STV (SEQ ID , were used as APCs. A Brachyury-
specific T cell line, denoted, TBR-A, was established. This T cell line was used in the
immunoassays described below.
Table 9 demonstrates that Brachyury-specific T cells (TBR-A) release
cant levels of IFN-y after stimulation with allogeneic DCs treated with 5,
whereas control yeast (YVEC, see Example 4) did not stimulate the e of IFN—y by T-
2-BR-A cells. Results are expressed in pg/ml/ 105 T cells. Briefly, allogeneic HLA-A2
positive DCs from a normal donor were treated with GI-6305 for 48 hours at various yeast
to DC ratios (indicated in Table 9) and then used to stimulate Brachyury agonist epitope-
specific T cells R-A). In this experiment, the DC to T cell ratio was 1:10.
Table 9
Dendritic Cells Yegjttilgc T Cells lFN-v
—————
—————
—————
——-——
——--m
——-——
——--m
——-——
Table 10 demonstrates that ury-specific T cells established by using
GI-6305 treated DCs can effectively lyse MDA-MB-23l breast cancer cells that are HLA-
A2 positive/Brachyury positive, but do not lyse ASPC-l pancreatic cancer cells that are
HLA-A2 negative/Brachyury ve. Briefly, the Brachyury-specific T cell line TBR—
A was used at IVS-6 in an overnight cytotoxic T lymphocyte (CTL) assay against MDA-
MB-23l (HLA-A2+/Brachyury+) and ASPC-l (HLA-A2'/Brachyury+) tumor cell targets,
at the indicated effector:target (ET) ratios (see Table 10). Results are expressed as the
percentage of specific lysis.
Table 10
ET ratio MDA-MB-231
azam 619m
nsum 02am
nsmm zsam
In another experiment, the ability of the TBR-A cell line to bind to
Brachyury-specific HLA-A2 tetramers was evaluated. Briefly, TBR-A cells (used at
IVS-4) were stained with a control tetramer or a tetramer specific for the Brachyury
agonist e. Figs. 7A and 7B show that 10.8% of CD8+ T cells in the TBR-A cell
line generated with 5-treated DCs specifically bind to a Brachyury-HLA-A2
tetramer (Fig. 7B) and not to a control tetramer (Fig. 7A).
Perforin expression of the TBR-A T cell line was analyzed by flow
cytometry (perforin is a mediator of the cytolytic actiVity of cytotoxic T lymphocytes
). Briefly, T cells were tested on day 5 after restimulation with Brachyury agonist
peptide-pulsed autologous EBV transformed B cells. Fig. 8 shows the expression of
perforin in the TBR-A cell line after ation with Brachyury agonist peptide-pulsed
autologous B cells, r demonstrating the cytotoxic capability of this Brachyuryspecific
T cell line, which was generated using 5-treated DCs.
Example 11
] The following e describes a phase 1 clinical trial in subjects with
Brachyury-positive cancer.
An open-label, sequential dose-escalation, phase 1 clinical trial has been
initiated using the yeast-Brachyury immunotherapy composition known as GI-6301,
described in Examples 1, 2, and 4-9. Under this clinical trial protocol, 9-18 cancer
patients (3-6 patients per dose cohort) are administered the yeast-Brachyury
immunotherapy composition known as GI-6301 in a sequential dose cohort escalation
ol utilizing dose ranges of 4 Y.U. (l Y.U. x 4 sites, meaning that l Y.U. of GI-6301
is administered at 4 different sites on the body of the patient each , 16 Y.U. (4 Y.U x
4 sites) and 40 Y.U. (lO Y.U. x 4 sites), administered subcutaneously. GI-630l is
administered at 2 week intervals for a total of 7 Visits (~3 months), and then y
thereafter until the patients meet off-study criteria. An expansion cohort of patients
(n=lO) at maximum tolerated dose (MTD) or the observed best dose are selected for
additional study. The s are monitoring safety and tolerability as a y endpoint,
and in the expanded cohort, whether a significant change in T cell precursors is detectable
as measured by an increase in Brachyury-specific T cells in ELISpot assay and
proliferation in response to Brachyury protein (e.g., Brachyury-specific CD8+ or CD4+ T
cells emerging or expanding on ent). As secondary endpoints, clinical benefit, such
as progression-free survival, clinical radiographic response, reduction in serum markers,
and/or reduction in circulating tumor cells is measured, as well as parameters of general
immune activation, including frequency of immune cell subsets in peripheral blood (CD8+
memory/effector T cells, CD4+ memory/effector T cells, Tregs, NK cells, DCs) and
changes in serum levels of cytokines (e.g., IFN-y, IL-10, IL-12, IL-2, IL-4, TGF-B, etc.).
GI-630l is expected to be safe and well-tolerated with no significant toxicities.
In addition, GI-630l is ed to e treatment-emergent Brachyury-specific T cell
responses or an improvement in isting Brachyury-specific baseline T cell responses
at least some or a ty of patients. Some patients are also expected to have stabilized
disease.
In an additional study or an ion of this study, the yeast-Brachyury
immunotherapeutic composition known as GI-6305 (see Example 3) is administered to an
additional cohort of patients, utilizing the maximum ted dose or observed best dose
determined above, and the same primary and secondary endpoints are measured. 5
is also expected to be safe and well-tolerated with no significant toxicities, as well as
produce treatment-emergent Brachyury-specific T cell responses or an improvement in
pre-existing ury-specific baseline T cell responses at least some or a majority of
patients. Some patients are also expected to have stabilized disease.
Example 12
The following example describes a phase 2 clinical trial using yeast-Brachyury
immunotherapeutic compositions.
A randomized phase 2 clinical trial in patients with breast cancer is run using a
yeast-Brachyury immunotherapeutic composition as bed in Example 1 and 2 (e.g.,
GI-630l) or in Example 3 (GI-6305). At least 100 or more subjects with Stage I, II or III
Brachyury-positive breast cancer are enrolled. Subject inclusion criteria can include
subjects with Grade 1, 2 or 3 cancers. t including criteria can also include subjects
with “triple negative” breast cancer (cancers that are ve for each of estrogen receptor
(ER), progesterone receptor (PR) and HER2). Subject inclusion criteria can also include
patients with lymph node-negative .
The trial is run as a double-blind or open-label, placebo-controlled, multi-
center trial. All patients receive standard of care therapy with treatment arm patients
receiving l serial injections of Brachyury immunotherapeutic composition
during ent. The primary endpoint is recurrence free survival or overall survival.
Additional endpoints can include antigen-specific T cell responses (e. g., Brachyuryspecific
CD8+ T cells emerging or expanding on treatment), nance of lymph node
negativity, ssion to metastases, and ury expression in tumor cells.
] The yeast-Brachyury therapeutic composition is expected to be safe
and well-tolerated with no significant toxicities. In addition, the yeast-Brachyury
immunotherapeutic composition is expected to produce treatment-emergent Brachyuryspecific
T cell responses and/or an improvement in pre-existing Brachyury-specific
baseline T cell responses in at least some or a majority of patients. Some or a majority of
patients are also expected to have stabilized disease, maintain lymph node negativity,
and/or tion, reduction or arrest in metastatic progression.
While various embodiments of the present invention have been described in
detail, it is apparent that modifications and adaptations of those embodiments will occur to
those skilled in the art. It is to be expressly understood, however, that such modifications
and adaptations are within the scope of the present invention, as set forth in the following
exemplary claims.
Claims (34)
1. Use of an immunotherapeutic composition comprising: a) a yeast vehicle; b) a cancer antigen comprising a Brachyury antigen, wherein the Brachyury antigen comprises SEQ ID NO:6, positions 2-435 of SEQ ID NO:6, SEQ ID NO:18, ons 2-435 of SEQ ID NO:18, or an amino acid sequence that is at least 85% identical to SEQ ID NO:18 and comprises a substitution of a leucine at position 254 with a valine; and c) an agent selected from the group ting of an immunotherapeutic virusbased vaccine, a cytokine, a T-cell co-stimulator, a modulator, CD40, anti-CTLA-4 antibody, anti-PD-1, anti-PD-L1, anti-PD-L2 and combinations thereof; in the manufacture of a medicament for treating cancer in an individual.
2. The use according to claim 1, wherein the Brachyury antigen comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:18 and comprises a substitution of a leucine at position 254 with a valine.
3. The use according to claim 1 or 2, wherein the Brachyury n comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:18 and comprises a substitution of a e at position 254 with a valine.
4. The use according to any one of claims 1 to 3, wherein the individual has a stage I cancer, stage II cancer, stage III cancer, or stage IV cancer.
5. The use according to any one of claims 1 to 4, wherein the cancer is ed from the group consisting of: breast cancer, small ine cancer, stomach cancer, pancreatic cancer, kidney cancer, bladder cancer, uterine cancer, n cancer, testicular cancer, lung cancer, colon cancer, prostate cancer, chronic lymphocytic leukemia (CLL), Epstein-Barr virus transformed B cells, Burkitt’s lymphoma, n’s lymphoma, and atic cancers thereof.
6. The use according to any one of claims 1 to 5, wherein the yeast vehicle is a whole yeast.
7. The use according to claim 6, wherein the whole yeast is killed.
8. The use according to claim 6 or 7, wherein the whole yeast is heat-inactivated.
9. The use according to any one of claims 1 to 8, wherein the yeast vehicle expresses the antigen.
10. The use according to any one of claims 1 to 9, wherein the yeast is from a genus selected from the group ting of: Saccharomyces, Candida, Cryptococcus, Hansenula, Kluyveromyces, , Rhodotorula, Schizosaccharomyces and Yarrowia.
11. The use according to Claim 10, wherein the yeast is from Saccharomyces cerevisiae.
12. The use according to any one of claims 1 to 11, wherein the composition is formulated in a ceutically acceptable excipient suitable for administration by injection to a subject.
13. The use according to claim 12, wherein the composition is formulated for administration in a dose from about 10 Y.U. to about 100 Y.U.
14. The use ing to claim 12, n the composition is formulated for administration in a dose from about 10 Y.U. to about 40 Y.U.
15. The use according to claim 12, wherein the composition is formulated for administration weekly, every other week, and/or monthly.
16. The use according to claim 12, wherein the immunotherapeutic composition is formulated for administration weekly for 5 weeks followed by monthly.
17. The use according to claim 12, wherein the composition is formulated for stration at two week intervals for seven rounds of treatment, followed by monthly.
18. The use according to claim 12, wherein the composition is ated as a single dose.
19. The use according to claim 12, wherein the composition is formulated for administration at more than one site on the subject.
20. The use according to claim 12, wherein the immunotherapeutic composition is formulated for concurrent administration with another therapy for cancer.
21. A inant nucleic acid molecule encoding a fusion n comprising at least one Brachyury antigen, wherein the ury antigen comprises SEQ ID NO:6, positions 2-435 of SEQ ID NO:6, SEQ ID NO:18, positions 2-435 of SEQ ID NO:18, or an amino acid sequence that is at least 85% identical to SEQ ID NO:18 and comprises a substitution of a leucine at position 254 with a valine, and wherein the fusion protein was sed by a yeast vehicle.
22. The recombinant nucleic acid molecule of claim 21, wherein the Brachyury antigen comprises SEQ ID NO:6.
23. The inant nucleic acid molecule of claim 21 or 22, wherein the Brachyury n comprises positions 2-435 of SEQ ID NO:6.
24. The recombinant nucleic acid molecule of claim 21, wherein the Brachyury antigen comprises SEQ ID NO:18.
25. The recombinant nucleic acid molecule of claim 21 or 22, wherein the Brachyury antigen comprises positions 2-435 of SEQ ID NO:18.
26. The inant nucleic acid molecule of claim 21, n the Brachyury antigen comprises an amino acid sequence that is at least 85% identical to SEQ ID NO:18 and ses a substitution of a leucine at position 254 with a valine.
27. The recombinant nucleic acid molecule of any one of claims 21-26, wherein expression of the ury fusion protein is under the control of a CUP1 promoter.
28. The recombinant nucleic acid molecule of claim 21, wherein the fusion protein has an amino acid sequence represented by SEQ ID NO:8, or an amino acid ce that is at least 85% identical to SEQ ID NO:8.
29. The recombinant c acid molecule of claim 21, wherein the fusion protein has an amino acid sequence ented by SEQ ID NO:20, or an amino acid sequence that is at least 85% identical to SEQ ID NO:20.
30. The recombinant nucleic acid molecule of claim 28, wherein the fusion protein has an amino acid sequence represented by SEQ ID NO:8.
31. The recombinant nucleic acid molecule of claim 21 or 29, wherein the fusion protein has an amino acid sequence represented by SEQ ID NO:20.
32. The recombinant nucleic acid molecule of claim 21, wherein the yeast vehicle is a whole yeast.
33. The inant nucleic acid molecule of claim 32, wherein the yeast is from a genus selected from the group consisting of: Saccharomyces, Candida, Cryptococcus, Hansenula, Kluyveromyces, Pichia, Rhodotorula, Schizosaccharomyces and Yarrowia.
34. The recombinant nucleic acid molecule of claim 33, wherein the yeast is from romyces cerevisiae.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161453656P | 2011-03-17 | 2011-03-17 | |
US61/453,656 | 2011-03-17 | ||
NZ711188A NZ711188B2 (en) | 2011-03-17 | 2012-03-19 | Yeast-brachyury immunotherapeutic compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ724797A NZ724797A (en) | 2020-06-26 |
NZ724797B2 true NZ724797B2 (en) | 2020-09-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11938175B2 (en) | Yeast-brachyury immunotherapeutic compositions | |
US11065318B2 (en) | Yeast-MUC1 immunotherapeutic compositions and uses thereof | |
NZ724797B2 (en) | Yeast-brachyury immunotherapeutic compositions | |
NZ724797A (en) | Yeast-brachyury immunotherapeutic compositions | |
NZ616696B2 (en) | Yeast-brachyury immunotherapeutic compositions | |
NZ711188B2 (en) | Yeast-brachyury immunotherapeutic compositions | |
NZ711188A (en) | Yeast-brachyury immunotherapeutic compositions |